Podcast appearances and mentions of Paul Armstrong

To provide some summer listening by the pool, and to act as a 'previously on...' for Season 4, AI has taken over the show and has complied some highlights from recent seasons.In this third of four episodes, our AI hosts GE0-RGE and L1-LLE, guide us through some of the conversations the team have had on important sustainability challenges, including...00:40 Paul Armstrong, Schneider Electric: What are the real sustainability challenges?05:35 Michael Crabb, Last Energy: The need for new sources of power11:48 Mark Butcher, Posetiv: What is net zero and what isn't?16:50 Mark Butcher: How to use sustainability dashboards21:36 Rainer Karcher, Allianz: How are companies addressing sustainability?23:52 Justin Keeble, Google: AI doesn't have to be a problem when it comes to energy use. 26:12 Mark Butcher: Important tips on how to startHostsGE0-RGE: Genuine Emote 0 - Repartee Generation Engine - currently doesn't have a LinkedInL1-LLE: Level 1 - Longform Loquaciousness Engine - currently doesn't have a LinkedInDave Chapman: https://www.linkedin.com/in/chapmandr/Sjoukje Zaal: https://www.linkedin.com/in/sjoukjezaal/Rob Kernahan: https://www.linkedin.com/in/rob-kernahan/ProductionNathaniel Tapley https://www.linkedin.com/in/nathanieltapley/Marcel van Der Burg: https://www.linkedin.com/in/marcel-vd-burg/Dave Chapman: https://www.linkedin.com/in/chapmandr/SoundBen Corbett: https://www.linkedin.com/in/ben-corbett-3b6a11135/Louis Corbett:  https://www.linkedin.com/in/louis-corbett-087250264/

Close friends of the recently departed Ducky Carlisle, Mike Gent and Paul Armstrong, join us on this episode to pay a lovely tribute to the late Boston based producer, engineer, musician. Mike and Paul tell some funny and heart warming stories about their late friend... Music The Figgs "Connecting Brains" Fireking "Futura 2000" additional music The Charms "So Pretty" The Dogmatics "I Love Rock N Roll" Check out music from podcast episodes here: https://open.spotify.com/playlist/6lHFZxDikYIabX6wKCGchE Produced and Hosted by Steev Riccardo

We are live from #MWC24 (Mobile World Congress 2024), direct from the Expo floor, with a limited series of episodes talking to leaders from across the industry on themes of the conference, as well as filling in on all of the news and gossip.Dave, Sjoukje and Rob explore the conference theme of 'Game Changers' by talking to three technology providers who are creating new solutions to solve some of our biggest challenges:Paul Armstrong, Global Sales Director, Digital Services, Schneider Electric about Smart Buildings and their critical role in helping businesses operating more sustainably and how having an 'Energy Command Centre' can helpGreg Pelton, CTO, Iridium and Richard Deakin, CEO, Stratospheric Platforms Ltd about the potential of non-terrestrial networks in both the stratosphere and low earth orbit to bring communications to previously hard to reach locations and space networks direct to consumer devices. They also talk about the difficulties in working in space!GuestsPaul Armstrong: https://www.linkedin.com/in/paul-armstrong-67871127/Greg Pelton: https://www.linkedin.com/in/greg-pelton-631789/Richard Deakin: https://www.linkedin.com/in/rdeakin/HostsDave Chapman: https://www.linkedin.com/in/chapmandr/Sjoukje Zaal: https://www.linkedin.com/in/sjoukjezaal/Rob Kernahan: https://www.linkedin.com/in/rob-kernahan/ProductionMarcel Van Der Burg: https://www.linkedin.com/in/marcel-van-der-burg-99a655/Dave Chapman: https://www.linkedin.com/in/chapmandr/SoundBen Corbett: https://www.linkedin.com/in/ben-corbett-3b6a11135/Louis Corbett:  https://www.linkedin.com/in/louis-corbett-087250264/

As AI sets its sights on revolutionising more and more industries, we ask if can AI change the face of hospitality with Paul Armstrong, Technology expert and founder of TBD group.

Having grown up in the restaurant tech industry together, longtime friends Alan Hayman, Paul Armstrong, and Kelly MacPherson and Accelerate host Rob Grimes reflect on what they've seen over the last 40 years (they started in Elementary School). From their individual experiences, they discuss their perspectives on what's happening now, and where they think things are headed for tech within the restaurant industries.In this candid chat, they begin by agreeing that the omnichannel approach operators must keep up with has made it even more complicated for independents to run their business. On the flip side, operators also don't have to settle with technology either now that there are more choices.The group touches on technologies like dynamic pricing and handheld devices that existed long before they were implemented and became popular for restaurants. Even AI, the hot topic of today, is like the rules-based systems that appeared 20+ years ago. And what about the “non-resettable grand total?”If you want to hear how tech has impacted and changed within operations over the years, and which innovations may take the lead looking forward - listen to this episode of Accelerate.

We're dancin' to the rhythm in our heart and soul, cuz it's S-A-T-U-R-D-A-Y Night on O3L! This week, we're all about the songs and albums that soundtrack our Saturday nights. And, yeah, we've got a Saturday Night Fever, and the only cure is... More FLASHCUBES! That's right...our Third Lads this week are bassist Gary Frenay and guitarist Paul Armstrong, one half of Power Pop Hall of Famers The Flashcubes! Gary and Paul, along with guitarist Arty Lenin and drummer Tommy Allen, burst out of Syracuse, NY in 1977. During their initial lifespan of 1977-1980, they released two singles, the classics "Christi Girl" and "Wait Til Next Week," and opened for major acts such as The Runaways, Ramones, The Jam and The Police. (In the case of the latter, here's a "true until proven otherwise" theory for you: Stewart Copeland is wearing a Flashcubes t-shirt on the cover of Regatta de Blanc.) Since the original foursome reformed in the late '90s as powerful and poppy as ever, they haven't looked back, with a string of acclaimed albums and a reputation as a world-class live act. The Flashcubes' latest album on Big Stir Records is Pop Masters, which finds our heroes tackling a selection of 12 guitar pop classics by their contemporaries, with an impressive roster of guest stars, including Pezband's "Baby It's Cold Outside" (with past O3L guest Mimi Betinis), Shoes' "Tomorrow Night" (with another past O3L guest, Jeff Murphy), The Paley Brothers' "Come Out And Play" and more. This is a must have for any power pop connoisseur! Plus, we unveil the latest world famous O3L game: Which Saturday Is It?, in which our discerning contestants distinguish between Saturday Night Fever quotes, Saturday Night Live lines, and lyrics from songs called "Saturday Night." It's gobs o' fun, we tell ya...gobs! Learn more about your ad choices. Visit megaphone.fm/adchoices

We're dancin' to the rhythm in our heart and soul, cuz it's S-A-T-U-R-D-A-Y Night on O3L! This week, we're all about the songs and albums that soundtrack our Saturday nights. And, yeah, we've got a Saturday Night Fever, and the only cure is... More FLASHCUBES! That's right...our Third Lads this week are bassist Gary Frenay and guitarist Paul Armstrong, one half of Power Pop Hall of Famers The Flashcubes! Gary and Paul, along with guitarist Arty Lenin and drummer Tommy Allen, burst out of Syracuse, NY in 1977. During their initial lifespan of 1977-1980, they released two singles, the classics "Christi Girl" and "Wait Til Next Week," and opened for major acts such as The Runaways, Ramones, The Jam and The Police. (In the case of the latter, here's a "true until proven otherwise" theory for you: Stewart Copeland is wearing a Flashcubes t-shirt on the cover of Regatta de Blanc.) Since the original foursome reformed in the late '90s as powerful and poppy as ever, they haven't looked back, with a string of acclaimed albums and a reputation as a world-class live act. The Flashcubes' latest album on Big Stir Records is Pop Masters, which finds our heroes tackling a selection of 12 guitar pop classics by their contemporaries, with an impressive roster of guest stars, including Pezband's "Baby It's Cold Outside" (with past O3L guest Mimi Betinis), Shoes' "Tomorrow Night" (with another past O3L guest, Jeff Murphy), The Paley Brothers' "Come Out And Play" and more. This is a must have for any power pop connoisseur! Plus, we unveil the latest world famous O3L game: Which Saturday Is It?, in which our discerning contestants distinguish between Saturday Night Fever quotes, Saturday Night Live lines, and lyrics from songs called "Saturday Night." It's gobs o' fun, we tell ya...gobs! Learn more about your ad choices. Visit megaphone.fm/adchoices

- Holy Name - Amy and Paul Armstrong - 21st Sunday in Ordinary Time (Spring). Broadcast on OAR 105.4FM Dunedin www.oar.org.nz

Welcome to The Arsenal Therapy Podcast, a dedicated show about the club we love, Arsenal Football Club. In this special edition of the podcast, we were forced to split it into 2 parts following a rare guest who shared all his secrets into the making of the Match of the Day. Paul Armstrong was the editor of the show for 30 years and even wrote a book titled "why are we always on last" where he describes what goes on in the background of the show and how the order of weekly games are determined. He also gives us his thoughts on how Arsenal performed this season, compares the current crop of players to past squads and what he believes we need to do in order to get to the next level. Part 2 of the show will be released on Wednesday where the boys discuss all the latest Arsenal related news and gossip. Stay tuned! Please let us know what you enjoyed about the podcast and do leave the podcast a 5-star review on Apple Podcast. Also, if you wanted to get in touch with us, you can do via Twitter: The Arsenal Therapy Podcast (@ArsenalTherapy) Farhan (@GunnerSince96) Adam (@AdamKeys_) Paul (@Armoaning)

Michelle Fern chats with earthbath CEO, Paul Armstrong. earthbath products are designed for the health of our beloved pets, people & the planet. They believe the ingredients that touch your pet's coat and skin should be as naturally effective, non-toxic, and gentle as possible for a better bath every time. EPISODE NOTES: earthbath

The Hole Truth is a Resources Rising Stars podcast hosted by Paul Armstrong, a seasoned expert in the world of finance and resources. With more than 30 years of experience as a finance journalist under his belt, Paul brings a wealth of knowledge and insight to his conversations with some of the most prominent figures in the industry. Each episode of The Hole Truth is a deep dive into the inner workings of those resources companies which are making things happen, quizzing those in charge about their projects, their prospects, the challenges they face and the opportunities they offer to investors. Whether you're an investor, industry professional, or simply interested in the latest developments in mining, energy, and resources, The Hole Truth is the podcast for you. Join Paul and his guests to hear about the latest investment opportunities in the resources sector.   ---- Produced by Resource Media ---- The Hole Truth is a product of Read Corporate. Please note that Read Corporate does not provide investment advice and investors should seek personalised advice before making any investment decisions. 

What do technology, behaviour and data have in common? My guest, Paul Armstrong, runs a conference called TBD and is a thought leader in how the three topics interconnect. As technology becomes smarter and more pervasive, what does that mean for human decision-making and human risk?Paul runs HERE/FORTH, an emerging technology advisory firm that works with a number of high-profile clients. As well as working in the technology industry in both the US and the UK, he has also written a book called "Disruptive Technologies” — the new revised version is just about to be published — and created the TBD Conference, an annual showcase of subjects relevant to technology, behaviour and data. In our discussion, Paul talks about how the conference came about.To find out more about Paul, visit his website: https://www.paularmstrong.co.uk/For more on TBD Conference: https://www.thetbdconference.com/ and the 2023 speakers: https://www.thetbdconference.com/speakersTo get 50% off ticket prices, use this exclusive link: https://www.universe.com/embed2/events/633466daac39cb002e4cfbb0?state=%7B%22currentDiscountCode%22%3A%7B%22code%22%3A%22TBDCONFHUMANRISK%22%7D%7DTo order Paul's new book: https://www.amazon.co.uk/Disruptive-Technologies-Practical-Understand-Disruption/dp/139860920XFor more on Paul's “What Did Amazon Do This Week” subscription newsletter: https://whatdidamazondothisweek.substack.com/Some of the things we mention on the show:Desire Paths, where humans chose routes other than the ones designers intended: https://www.theguardian.com/cities/2018/oct/05/desire-paths-the-illicit-trails-that-defy-the-urban-plannersThe Welsh example I refer to: https://www.reddit.com/r/therewasanattempt/comments/nvgxef/to_stop_people_walking_on_the_grass/ Affordances: https://danewesolko.medium.com/the-theory-of-affordances-cb51fd138b3e The book ‘Winning Not Fighting': https://www.winningnotfighting.com/ Behavioural Science guru Rory Sutherland. Here's his first appearance on the show: https://www.humanriskpodcast.com/rory-sutherland-on-compliance/ Miss Yankey, the slam poet Paul invites to do readings at TBD: https://www.missyankey.com/ Sedition, digital art: https://www.seditionart.com/ Finally, to pre-order my new book, 'Humanized Rules: Bringing Behavioural Science to Ethics & Compliance', visit https://www.linktr.ee/humanizingrules. Keep your receipt, and you'll get access to exclusive content and events.

Coach Paul Armstrong-Rapid Fire Questions

Coach Paul Armstrong is originally from Burnsville, where he grew up playing soccer, baseball, and basketball. He is a graduate of Burnsville High School where he competed in basketball and soccer. After high school, Paul attended Luther College where he played soccer. After graduating from college, Paul coached at the Shakopee Soccer Association, The Blake School, St. Paul Academy, and is now in his first year as the head coach of the girls soccer team.

In this episode, the new President of the ICGP, Dr Paul Armstrong, describes his vision for general practice, the challenges facing GPs, and his experience in helping create community housing projects. Dr Armstrong is based at the Lifford & Castlefinn Primary Care Centre, in Lifford, Co Donegal, on the border with Strabane, in northern Ireland. We recorded this episode in his surgery there. To find out more about the Irish College of General Practitioners, go to www.icgp.ie. To contact this podcast, email ICGP.news@gmail.com

The unmistakeable sound of Melissa Brinton is prolifically filling a good share of the Berkshire music scene, as she performs solo and in two additional groups. She's perhaps the busiest musician in the region. Ironically, it may have been during the lockdown that Melissa elevated to a new level as the pandemic encouraged innovation and greater creativity. Unable to play and perform in any public venue, Melissa took to social media taking requests. She responded to the requests for tunes that she likely never would have considered learning before, and put a beautiful spin on many of our favorites. That inspiration has led to an evolution of her own sound as she works on music for her third album. In this episode, Melissa performs new music that will be on her new album as well as a few covers that you're sure to love. We also cover Melissa's vocal education at Pittsfield High School under the legendary Gaylan Palmer, techniques for improving vocal performance, her Irish music repertoire, playing with Fanny Pack with Elaine Morel and Paul Armstrong, as well as Flight with Mary Verdi and Eileen Markland, recording with her Father and her musical brother, Christopher, folky versions of Frank Sinatra songs, inspiration from the Spotify algorithm and more. I hope you'll enjoy my conversation and the music of Melissa Brinton.  --- Support this podcast: https://anchor.fm/john-krol/support

December 17, 1993. Merced, California. 27-year old Paul Armstrong, a tow truck operator employed by RTS Towing, vanishes without explanation from his home. Later that day, 34-year old Steven Lombard, another tow truck operator from the same company, goes to the towing yard to pick up his paycheque before he also disappears and his abandoned pick-up truck is found in a K-Mart parking lot the following morning. Over 15 years later, the owner of RTS Towing, Randal Wright, becomes a person of interest in the disappearance of his 50-year old estranged wife, Karen Wright, who vanishes from their vacation home in Mexico. While there is suspicion that Randal might have been involved in all of these disappearances, no trace of any of the victims is ever found. On this week's episode of “The Trail Went Cold”, we will be covering a trio of unsolved missing persons cases and explore whether or not they are actually connected to each other. After that… the trail went cold. If you have any information about this case, please contact the Merced County Sheriff's Office at (209) 385-7445. Thanks Ana Luisa. Get 10% off at shop.analuisa.com/cold by using the promo code “cold”. Additional Reading: https://charleyproject.org/case/paul-henry-armstrong https://charleyproject.org/case/steven-lincoln-lombard https://www.mercedsunstar.com/latest-news/article3240379.html https://abc30.com/archive/6719241/ https://sanbenito.com/updated-former-local-missing-in-mexico-for-3-months/ https://www.mcclatchydc.com/news/crime/article24554236.html https://www.mercedsunstar.com/news/local/article3251777.html https://www.modbee.com/latest-news/article3127847.html https://www.modbee.com/latest-news/article3133722.html https://www.newspapers.com/image/784386582/ https://www.newspapers.com/image/784386631 https://www.newspapers.com/image/667636945/ “The Trail Went Cold” is on Patreon! Visit www.patreon.com/thetrailwentcold to become a patron and gain access to our exclusive bonus content. “The Trail Went Cold” is going to be appearing on podcast row at “Crimecon UK” at the Leonardo Royal Hotel &  Spa in London on June 11-12, 2022. To get a 10 % discount on the purchase of tickets to the event, please use our specialized promo  code, “COLD22”, by visiting https://www.crimecon.co.uk. “The Trail Went Cold” is now doing a weekly livestream show on  GetVokl every Thursday from 7:00-8:00 PM ET as part of their “True  Crime Thursday” line-up. For more information, please visit their website. The Trail Went Cold is produced and edited by Magill Foote. All music is composed by Vince Nitro.

December 17, 1993. Merced, California. 27-year old Paul Armstrong, a tow truck operator employed by RTS Towing, vanishes without explanation from his home. Later that day, 34-year old Steven Lombard, another tow truck operator from the same company, goes to the towing yard to pick up his paycheque before he also disappears and his abandoned […]

Hello, I'm Paul Armstrong, host of mouthwash, the show that offers fresh chat to leave you feeling more confident.This season we're looking at the real future of work. A lot has been said about where the office is or isn't going. And I want to find out if the great resignation is here to stay - or if people just fancy to change. We're going to be exploring workplace culture, design and remote working. We'll also be looking into the future of co-working and the big one, your purpose.Joining me to answer these and other big questions are a myriad of incredibly smart and interesting people, including multiple best selling authors from Dan Pink and Gretchen Rubin, to behavioural psychologist and economist Rory Sutherland to New York Times, Rob Walker, TikTok's job Doctor Tessa White, Emily Logan from Noble Collective, and Esther O'Callaghan from hot new startup called hundo that you'll be finding out about.There are 20 episodes this season and I am pleased to have workplace by Meta onboard as our sponsors. Ecologi who are planting a tree for every live listener we get on Twitter Spaces is also back. And the season starts at 8pm on April 5, so you can find out more and download the full calendar over at mouthwashshow.com or head to mouthwash.norby.com. and you'll be able to sign up for SMS alerts to find out when we go live. See you there!Music: Lofi Hip Hop by Coma Media http://pixabay.com/music/beats-lofi-hip-hop-11489/ Hosted on Acast. See acast.com/privacy for more information.

On this week’s show we are joined by Matt Cockbill from Berwick Partners to talk about The Great Resignation, and changing tides in the world of technology leadership. This week we also have a special offer with 25% off tickets to Paul Armstrong’s TBD Conference at the end of March. Find out more here https://www.thetbdconference.com/ […]

Happy New Years Insiders! Another Eye Opening Stream For You This Week!!

Please join author Ole Fröbert and Associate Editor Dharam Kumbhani as they discuss the article "Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast, summary and backstage pass to the journal and its editors. We're your co-hosts. I'm Dr. Carolyn Lam, associate editor from the National Heart Center in Duke National University of Singapore. Dr. Greg Hundley: I'm Dr. Greg Hundley, associate editor, director of the Poly Heart Center at VCU health in Richmond, Virginia. Well, listeners, this week we've got a really hot feature topic pertaining to flu vaccines, which are coming in the US, North America, South America, coming up soon, and their relationship to myocardial infarction. But before we get to that feature discussion, let's grab a cup of coffee and jump in to some of the other articles in this issue. Oh, wait a minute. Our first article, we've got a co-author here. Carolyn, something about the VICTORIA trial, which you were a part of. Can you tell us a little bit about this? Dr. Carolyn Lam: I would love to, and first of all, I'm doing this on behalf of a big team, and I want to really, really call up first Dr. Paul Armstrong who's the senior author from University of Alberta. But let me tell you first about the VICTORIA study. VICTORIA evaluated vericiguat, a soluble guanylate cyclase stimulator, compared to placebo, in patients with heart failure with reduced ejection fraction with a recent worsening heart failure event and the primary result was actually a significant reduction in the primary composite outcome of cardiovascular death or heart failure hospitalization with vericiguat compared to placebo. Dr. Carolyn Lam: Now, interestingly though, in VICTORIA, we found that anemia occurred more often in patients treated with vericiguat at a rate of about 7.6% compared to placebo, which was 5.7%. Now, although earlier studies of another soluble guanylate cyclase stimulator like riociguat was found to be associated with anemia. The etiology really remains unknown. In the current paper, we explored the relationship between markers of anemia and vericiguat versus placebo in VICTORIA. We further explored the changes in hemoglobin and hematocrit over the course of the trial and their relationships with the primary composite outcome. Dr. Greg Hundley: Carolyn, this is such an important new study heart failure therapy for those with reduced ejection fraction, and again, an important topic related to anemia. What did they find? Dr. Carolyn Lam: Thanks, Greg. First, approximately a third of patients in VICTORIA had anemia at randomization, and this is using the standard sex-based definitions. With a lower hemoglobin indeed predicting a higher risk for cardiovascular death, heart failure hospitalization, all-cause mortality. As I had already mentioned, we found more anemia with vericiguat than with placebo. The interesting thing though is after 16 weeks, no further decline in hemoglobin occurred over the remaining and over 96 weeks of follow up, and the ratio of hemoglobin to hematocrit remained constant. Now, overall, the adverse event of anemia occurred in 7.1% of the patients. Dr. Carolyn Lam: Importantly, the lower hemoglobin was not related to the beneficial effect of vericiguat over placebo on the primary outcome. Now, I know all of that may be more descriptive and reassuring than really understanding the mechanism by which it occurred. Further mechanistic studies are certainly warranted to better understand the basis of the anemia development, and it's of principle importance because as you said, vericiguat I think it's going to be an important new medication that we can consider in high-risk patients with recent worsening heart failure with reduced ejection fraction. Dr. Greg Hundley: Thanks so much, Carolyn, especially the perspective of being an author on this particular study. Well, Carolyn, my next study is going to come to us from Dr. Zhao Wang from University of Texas Southwestern Medical Center, and it's really about the integrated stress response, and that's an evolutionary conserved process to cope with intracellular and extracellular disturbances. Myocardial infarction is a leading cause of death worldwide. Coronary artery perfusion is the most effective means to mitigate cardiac damage resulting from myocardial infarction. However, that can cause, as we know, additional reperfusion injury. This study aim to investigate the role of the integrated stress response in myocardial ischemia reperfusion injury. Dr. Carolyn Lam: Oh, very interesting. What were the results? Dr. Greg Hundley: Right, Carolyn. The authors found that the integrated stress response is activated by ischemia reperfusion injury in the heart, and the perk branch of the integrated stress response protects the heart from ischemia reperfusion injury through inhibition of protein synthesis. Also, Carolyn, mitochondrial complex proteins are selectively suppressed and oxidative stress is reduced by the integrated stress response. Carolyn, the takeaway is that this integrated stress response is cardioprotective against cardiac ischemia reperfusion injury. Perhaps pharmacological stimulation of the integrated stress response at reperfusion, well, that may reduce heart damage and improve cardiac outcomes after ischemia reperfusion injury. Dr. Carolyn Lam: Cool. Thanks, Greg. Well, I've got one more paper, and this deals with coronary microcircuitry dysfunction and acute rejection after heart transplantation. Co-corresponding authors, Doctors Lee and Choi from Heart Vascular Stroke Institute in Samsung Medical Center sought to evaluate the prognostic implications of coronary microcircuitry dysfunction assessed by the index of microcircuitry resistance or IMR for the risk of acute cellular rejection after heart transplantation. They did this by prospectively enrolling 154 heart transplant recipients who underwent scheduled coronary angiography and invasive coronary physiological assessment one month after transplantation.   Dr. Greg Hundley: Very interesting, Carolyn. What did they find here? Dr. Carolyn Lam: IMR measured early after heart transplantation was significantly associated with the risk of acute cellular rejection, and an IMR above or at 15 was highly predictive for the recurrence of acute cellular rejection during two years of follow up following heart transplantation. Adding IMR to the prediction model with clinical variables significantly increase discriminant and reclassification ability for the risk of acute cellular rejection. In addition to surveillance endomyocardial biopsy, the implications are that early stratification using IMR could be a clinically useful tool to identify patients at higher risk of future acute cellular rejection after heart transplantation, and this is discussed in an editorial by Doctors Fearon and Valentine from Stanford University. Dr. Greg Hundley: Very nice, Carolyn. Dr. Carolyn Lam: Great. Greg, before we go to the exciting feature discussion, let's round it up by just a quick tour of what else there is in today's issue. There is an exchange of letters between Doctors Pappone Leor on atrial fibrillation as a cardiomyopathy, global rounds on United Kingdom by Dr. Cowie, an ECG challenge by Dr. Tsai on grouped beating following acute inferior myocardial infarction, and a research letter by Dr. Salem on electrocardiographic manifestations of immune checkpoint inhibitor myocarditis. Dr. Greg Hundley: Great, Carolyn. Well, I can't wait to get to this next feature discussion and learn a little bit more about the relationship between flu vaccines and future myocardial infarction. Dr. Carolyn Lam: Today's feature discussion was a really hot topic at the ESC 2021, and in fact, a simultaneous publication. It is about influenza vaccination after myocardial infarction, a very important topic and a very novel paper. We are so pleased to have the first and corresponding author, Dr. Ole Fröbert from Orebro University in Sweden to discuss this paper, as well as our associate editor, Dr. Dharam Kumbhani, from UT Southwestern. Welcome, gentlemen. Only if I could start with asking you to describe the rationale for why you did this study, and then perhaps quickly summarize the results. Dr. Ole Fröbert: Yeah, thank you so much, Carolyn. The background of the study was that during influenza epidemics, more people die from cardiovascular causes, and out in the literature, there are numerous observational studies suggesting a protective effect from influenza vaccination on cardiovascular events. There are also three smaller single-center randomized trials supporting these registered findings. Currently influenza vaccination carries a Class I, Level of Evidence B recommendation in both American and European secondary prevention guidelines, but uptake is low and vaccination timing is unclarified. Our aim was to determine whether influenza vaccination improves clinical outcomes in patients with a recent myocardial infarction or with high risk corona artery disease. Dr. Ole Fröbert: The study was international, multi-centers investigator initiated, double-blind randomized control trial, and we enrolled patients at 30 centers across eight countries in both the Northern and the Southern Hemisphere, Sweden, Denmark, Norway, Latvia, Scotland, Czech Republic, Bangladesh and Australia. We enrolled patients between October 2016 and March 2020. We had quite broad inclusion criteria. We included hospitalized patients with STEMI or non-STEMI, or high-risk stable patients over 75 years of age undergoing an angio or PCI. We excluded patients already vaccinated or intending to be vaccinated during the current season. We also included, of course, patients if they had allergy to X or influenza vaccine, if they had infection or if they were immunosuppressed or previously randomized in the trial. Dr. Ole Fröbert: Over these four years of inclusion, we enrolled a total of 2,571 participants. The primary outcome was a composite of all-cause death, MI and stent thrombosis. This outcome occurred in 67 participants assigned influenza vaccine and 91 assigned placebo corresponding to a reduction of the primary endpoint of 28% with a P value of 0.04. Also, rates of all-cause death and of cardiovascular death were reduced and both with a hazard ratio of 0.59 corresponding to a reduction of 41% in all-cause death and cardiovascular death. Based on these results, we think that this trial and what we know from previous smaller trials should be sufficient to establish influenza vaccination as a new standard of care as part of in-hospital treatment after an MI. Dr. Carolyn Lam: Heartfelt congratulations, Ole. What an elegant intervention in a very frankly challenging situation that the trial obviously carried on through COVID as well, multinational. May I just double check? Was it investigator-led? Because- Dr. Ole Fröbert: Yes, this was- Dr. Carolyn Lam: That's amazing. Dr. Ole Fröbert: ... an idea that just popped up, and then yeah, we did it, but it was seven years of work. Dr. Carolyn Lam: Wow. Hard work as I can just imagine. First, heartfelt congratulations. Very impactful results. Dharam, could I invite you to put those results in context and why we single this out? Dr. Dharam Kumbhani: Yeah. No, thank you, Carolyn. Ole, I want to amplify or recapitulate the amazement and wonder that Carolyn just articulated. I think this is a huge endeavor. It's a very important topic. It's "a fairly simple intervention." It's vaccination, and you've just really shown that even in the acute setting, that A, this is as feasible, B, it is safe, and three, it is effective. I think it's potentially ... Given the magnitude of influenza in the world, I think this has tremendous public health ramifications. I really want to congratulate you and your investigators for pursuing this important question and then just executing this, I'm sure despite multiple challenges over a long period of time. Dr. Ole Fröbert: Thank you very much. Dr. Dharam Kumbhani: Yeah, no. I guess you already alluded to the fact that this may influence guidelines. As you mentioned, it's a 1B. Maybe get your thoughts, I suppose this may move the needle towards becoming perhaps a little stronger on the recommendation front, both in the US and the European guidelines? Dr. Ole Fröbert: Yeah. I think what has been the challenge until now is that many places, of course, you commend patients to take a flu jab when treatment is over in the hospital. But then the responsibility is diffused. Who should take care of that? Is that up to the patient or the primary care physician? Who is in charge? One important finding of this study is, as you said, it's safe. There were no differences, adverse events between the two groups. It's safe and it could be given early. I think a take-home factor from the study is that it should be given at the hospital and it's a responsibility of the cardiologist. Dr. Dharam Kumbhani: Yeah, I really like that. Actually, I'm sure this would resonate across the board in the cardiology community. We've taken ownership for starting from statin and now SGLT-2 inhibitors, which kind of ... All of these medications have come from non-cardiology realms, so to say. But now we prescribe those medications. We know they have clear cardiovascular benefits. I suppose you could make a case to say we, the cardiology community, has to adopt this. The implementation gap that exists for a lot of these therapies, that also comes to us and for us to move that forward. It's thought provoking. I certainly felt very strongly after your study. I don't know how you feel about that. We should really be the ones driving this and help with more widespread immunization in these patients. Dr. Ole Fröbert: I think because not just this study, but also the previous studies and what we know from observational findings is that this is safe and it works. What we also saw in our study, and it has been indicated in previous meta analysis, is that the maximum effect is seen in the acute setting. It's the acute coronary syndrome patients, the patients we had in our study, that benefit the most. That's also a case for actually doing this in the hospital and not postponing it. Dr. Carolyn Lam: Wow. That's amazing. Ole, I do have one question. Just for clarification. You were careful to say that you did this during influenza seasons, right? Coming from my part of the world in Singapore where we don't really have influenza seasons, don't have any seasons, frankly, what would you think? What would you advise? Dr. Ole Fröbert: There is influenza seasons in all parts of the world, I'm sorry. Dr. Carolyn Lam: True. Dr. Ole Fröbert: For example, we had Bangladesh on board in our study. It's in the Northern Hemisphere, but influenza-wise, it's in the Southern, and their season is between May and September. But it's not as clearly defined as the Northern Hemisphere season. It's almost always in two waves during that season. One practical challenge with influenza vaccine is that it's produced for the seasons. It's difficult to say, "Yeah, we can just do it all year round," and also we didn't test that. I, of course, feel we should give it all year round, but it's not available, the vaccine. Perhaps it should be tested, but it is probably difficult to find funding for such a study. Dr. Carolyn Lam: Very fair, and thanks for the correction. It's true though. Singapore's on the Equator, so we don't have maybe weather seasons. But yeah, we do get vaccinated for both North and South. It's quite fascinating. But nonetheless, could I now switch topics a little bit and just over the next couple of minutes just ask you, could you please perhaps share with the audience what it was like to work with Circulation, to do this simultaneous publication? You see, our associate editor, Dharam Kumbhani, really leads this effort to get simultaneous a fast-track publication from major conferences, and it means a lot to us that investigators like you chose us. Could you share a bit? Dr. Ole Fröbert: Yeah, thank you very much. Overall, it was a pleasure. Of course, we were ... With every study of this size, you are under stress, you get the results late, and there's a conference coming up, and you would like your paper to come out at the same time across to maximize impact and attention. What I really like with working with Circulation was turnaround time was ultra fast, really extremely fast. Of course, we had a lot of questions to our study, but these were ... Some of them of course were quite difficult, but they were fair. In a way, they were also helpful in a way that made it easier to address the questions in a more, you could say, collaborative way. It was very smooth. No hiccups. Dr. Carolyn Lam: Thank you. Dharam, any final responses to that? Dr. Dharam Kumbhani: No, thank you, Carolyn. Yeah. Well, Ole, it was really a pleasure to work with you on this. I think we all recognize that this was an important study and wanted to make sure that we were able to accomplish the goal of simultaneous publication. Thank you for working with us on that. I just want to put a pitch in, I think this, for Joe, Dr. Hill and the rest of the editorial team, having a robust simultaneous publication program has been very, very important. We are very committed to working with investigators and authors on this. We are really blessed with our team on the backside that works seamlessly with us nights, weekends, just to get these things done. I just want to end with that to say this is very important for us, and we look forward to the opportunity to work with Ole and others on future papers as well.   Dr. Carolyn Lam: I love that. Thank you both for being on this podcast today. Today I want to especially call out David Rivera, a wonderful managing editor who really, really is part of leading this entire group that supports us, but also even this very podcast. You've been listening to Circulation on the Run. Thank you, from both Greg and I, for joining us today, and don't forget to tune in again next week. Thank you. Dr. Greg Hundley: This program is copyright of the American Heart Association 2021. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, visit ahajournals.org.

Join Scott, Larry and Greg as we have a relaxed conversation with fellow cigar smoker, Tobacco Republic patron and UK transplant Paul Armstrong.  We how you all enjoy and please remember to share this podcast on your social media feeds.

The Dungeoneers have got Simone Biles's back. And they're smelling great in the process. We love you. Love us back. Your mom probably told you that you can't buy friendship. We're saying she is wrong. Visit itsonlytwodollars.com and become a patron of the show. Absolve the latent guilt you've been carrying all these years. $5.00 friends gain access to a bonus feed of exclusive content. Aftershow topics, shenanigans, and awkward good nights can be yours. Support the show. Your conscience will be as clear as Paul's colon.

The Dungeoneers discuss camping, armadillo leprosy, and the penultimate episode of "Loki." We love you. Love us back. Your mom probably told you that you can't buy friendship. We're saying she is wrong. Visit itsonlytwodollars.com and become a patron of the show. Absolve the latent guilt you've been carrying all these years. $5.00 friends gain access to a bonus feed of exclusive content. Aftershow topics, shenanigans, and awkward good nights can be yours. Support the show. Your conscience will be as clear as Paul's colon.

CME credits: 0.25 Valid until: 30-06-2022 Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-on-new-therapy-combinations-for-hfref-raising-clinician-awareness/12691/ Is it possible to reduce the nearly 60% one-month rehospitalization rates in patients with worsening heart failure? Dr. Paul Armstrong and Dr. Justin Ezekowitz discuss new therapeutic combinations including soluble guanylate cyclase (sGC) stimulators, as well as the practical applications of new evidence that was presented at the 2021 annual ACC meeting that may change how physicians approach treating their patients with worsening heart failure. Don't miss out on new information about how sGC stimulators may benefit your patients.

CME credits: 0.25 Valid until: 30-06-2022 Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-on-new-therapy-combinations-for-hfref-raising-clinician-awareness/12691/ Is it possible to reduce the nearly 60% one-month rehospitalization rates in patients with worsening heart failure? Dr. Paul Armstrong and Dr. Justin Ezekowitz discuss new therapeutic combinations including soluble guanylate cyclase (sGC) stimulators, as well as the practical applications of new evidence that was presented at the 2021 annual ACC meeting that may change how physicians approach treating their patients with worsening heart failure. Don't miss out on new information about how sGC stimulators may benefit your patients.

What will happen to all the spare office buildings? We love you. Love us back. Your mom probably told you that you can't buy friendship. We're saying she is wrong. Visit itsonlytwodollars.com and become a patron of the show. Absolve the latent guilt you've been carrying all these years. $5.00 friends gain access to a bonus feed of exclusive content. Aftershow topics, shenanigans, and awkward good nights can be yours. Support the show. Your conscience will be as clear as Paul's colon.

Paul's wife Sonya comes on the show to explain why Paul needed to protect himself. We love you. Love us back. Your mom probably told you that you can't buy friendship. We're saying she is wrong. Visit itsonlytwodollars.com and become a patron of the show. Absolve the latent guilt you've been carrying all these years. $5.00 friends gain access to a bonus feed of exclusive content. Aftershow topics, shenanigans, and awkward good nights can be yours. Support the show. Your conscience will be as clear as Paul's colon. Special Guest: Sonya Armstrong.

We love you. Love us back. Your mom probably told you that you can't buy friendship. We're saying she is wrong. Visit itsonlytwodollars.com and become a patron of the show. Absolve the latent guilt you've been carrying all these years. $5.00 friends gain access to a bonus feed of exclusive content. Aftershow topics, shenanigans, and awkward good nights can be yours. Support the show. Your conscience will be as clear as Paul's colon.

We love you. Love us back. Your mom probably told you that you can't buy friendship. We're saying she is wrong. Visit itsonlytwodollars.com and become a patron of the show. Absolve the latent guilt you've been carrying all these years. $5.00 friends gain access to a bonus feed of exclusive content. Aftershow topics, shenanigans, and awkward good nights can be yours. Support the show. Your conscience will be as clear as Paul's colon.

We love you. Love us back. Your mom probably told you that you can't buy friendship. We're saying she is wrong. Visit itsonlytwodollars.com and become a patron of the show. Absolve the latent guilt you've been carrying all these years. $5.00 friends gain access to a bonus feed of exclusive content. Aftershow topics, shenanigans, and awkward good nights can be yours. Support the show. Your conscience will be as clear as Paul's colon.

We love you. Love us back. Your mom probably told you that you can't buy friendship. We're saying she is wrong. Visit itsonlytwodollars.com and become a patron of the show. Absolve the latent guilt you've been carrying all these years. $5.00 friends gain access to a bonus feed of exclusive content. Aftershow topics, shenanigans, and awkward good nights can be yours. Support the show. Your conscience will be as clear as Paul's colon.

Dr Paul Armstrong, Lifford based GP and former Covid assessment hub lead has the latest on the situation in Donegal.

Paul Armstrong, founder of Here/Forth, a London-based emerging technology advisory firm

Clubhouse is the hot new social audio star. But Twitter Spaces is available to 30X the audience out of the box … and draws on a social graph you already own. Does that mean it’s the new winner just waiting to be crowned? In this episode of TechFirst with John Koetsier, I chat with Paul Armstrong, CEO and founder of Here/Forth … and owner of the very first sponsored show on Twitter Spaces … sponsored by a Fortune 500 global brand, too yet. At least, as far as Armstrong knows. Links: Support TechFirst with $SMRT coins: https://rally.io/creator/SMRT/ TechFirst transcripts: https://johnkoetsier.com/category/tech-first/ Forbes columns: https://www.forbes.com/sites/johnkoetsier/ Full videos: https://www.youtube.com/c/johnkoetsier?sub_confirmation=1 Keep in touch: https://twitter.com/johnkoetsier

We love you. Love us back. Your mom probably told you that you can't buy friendship. We're saying she is wrong. Visit itsonlytwodollars.com and become a patron of the show. Absolve the latent guilt you've been carrying all these years. $5.00 friends gain access to a bonus feed of exclusive content. Aftershow topics, shenanigans, and awkward good nights can be yours. Support the show. Your conscience will be as clear as Paul's colon.

We love you. Love us back. Your mom probably told you that you can't buy friendship. We're saying she is wrong. Visit itsonlytwodollars.com and become a patron of the show. Absolve the latent guilt you've been carrying all these years. $5.00 friends gain access to a bonus feed of exclusive content. Aftershow topics, shenanigans, and awkward good nights can be yours. Support the show. Your conscience will be as clear as Paul's colon.

CME credits: 0.25 Valid until: 31-03-2022 Claim your CME credit at https://reachmd.com/programs/cme/new-therapies-offer-improved-outcomes-in-hfref-management/12347/ Finding the optimal treatment strategy for patients with worsening heart failure with reduced ejection fraction (HFrEF) can be challenging, and long-term outcomes are poor. Can newer therapies and novel mechanisms of action finally help close the treatment gap for these patients? Join Drs. Javed Butler and Paul Armstrong as they explore these new mechanisms of action and provide practical insights into incorporating newly approved therapies into an overall HFrEF treatment plan.

CME credits: 0.25 Valid until: 31-03-2022 Claim your CME credit at https://reachmd.com/programs/cme/new-therapies-offer-improved-outcomes-in-hfref-management/12347/ Finding the optimal treatment strategy for patients with worsening heart failure with reduced ejection fraction (HFrEF) can be challenging, and long-term outcomes are poor. Can newer therapies and novel mechanisms of action finally help close the treatment gap for these patients? Join Drs. Javed Butler and Paul Armstrong as they explore these new mechanisms of action and provide practical insights into incorporating newly approved therapies into an overall HFrEF treatment plan.

Talking with Journalist Paul Armstrong on what it is like to cover the most ambitious company of our generation. Every week Paul gives interesting information regarding the company and helps us have the best of the best. Check it out. https://whatdidamazondothisweek.substack.com/

Paul Armstrong from the San Diego Rescue Mission stops by to share the work that they do to help homelessness, how faith plays a role in their programming and how they measure the impact that they are having each day. We talk about how to expand your impact from helping individuals to helping entire communities.

In this podcast, expert clinicians will discuss the safety and efficacy of sGC modulators that was seen in various clinical trials.

In this podcast, expert clinicians will discuss the mechanism of action of sGC modulators and the rationale for its use in patients with heart failure.

In this podcast, expert clinicians will discuss the burden of heart failure in the United States and the potential of new therapies for treating heart failure.

In this podcast, expert clinicians will discuss the potential use of sGC modulators in the management of patients with heart failure with reduced ejection fraction (HFrEF).

This week: Stephen starts out British, Mark gets all the references, and Ellen makes octopus noises. We talk high-level about what it takes to make (and market) games for young children, and Mark shares some insights about comedy in games—can it be more than silly memes? Maybe!COMING SOON!- PATREON?!!- EPISODE 200??!!!WOOOHOOOO!!!!!! Games for Young Children 0:10:42 Ellen Burns-JohnsonGame DesignMarketingDesigning for Youth - Making Games for Players Under 14 - Extra Credits, YouTubeDesigning Apps and Games for Kids (The Right Way) - Paul Armstrong, Carly Gloge, Jim Nichols, Alex Bowman, GDCCar Wash Game for Kids (gameplay video) - YouTubeZen Koi - Game for iOS and Android - LandShark GamesScratch from MIT"Scratch helps young people learn to think creatively, reason systematically, and work collaboratively — essential skills for life in the 21st century." Ellen mentioned children's franchises Blues Clues, "Baby Shark" from Pinkfong, and P.J. Masks. Comedy in Games 0:44:16 Mark LaCroixGame DesignNarrativeWe mentioned the following games and game series during this part of the roundtable:Ratchet and ClankJob SimulatorOctodad: Dadliest CatchInflatalityDivekickThe Stanley Parable

We started off this week's show with an interview that Niko did with Paul Armstrong who is the executive director of Crazy8s. After that, we had two very positive reviews. First one being Serra's review on Studio 58's "The Doll's House Project". Serra actually interviewed one of the actors in this production, Sierra Haynes, so make sure to check out last week's episode for that! After Serra, Silvana did her review on "Brother, I Cry" which was part of VIFF. Fun fact, Serra also did an interview with Jessie Anthony who is the writer, producer and director of Brother, I Cry. If you want to listen to that interview, it's on the episode of September 30th! We finished off the show with some shout-outs to the Discover Dance Series, to VIDF Livestreams and lastly to VSFF Call for submissions. Submit your short film until the 16th!

Dr Paul Armstrong, Lifford-based GP, and Connie Duffy, Senior Journalist with the Donegal Democrat, discuss further Covid-19 restrictions to be imposed on Donegal amid rising cases in the county

Alias Jimmy Valentine is an old-time radio crime drama in the United States. It was broadcast on NBC-Blue January 18, 1938 - February 27, 1939. Format: The concept for Alias Jimmy Valentine came from writer O. Henry in his short story A Retrieved Reformation. That story was adapted into the 1910 play Alias Jimmy Valentine by Paul Armstrong. The program's stories focused on Lee Randall, described by Jim Cox in his book, Radio Crime Fighters: More Than 300 Programs from the Golden Age as "an ex-con and reformed safecracker who applied his talents and enormous underworld contacts to abet the forces of law and order." While doing so, he became an honest bank clerk and fell in love with the daughter of the banker.

Welcome to the Lancaster Story Slam podcast!  Our Story Slam theme in August was “Firsts.” We heard eight stories from our wonderful storytellers. Our winner by audience vote for was Randy Shultz with his tale of trouble with a sheepish grin. Randy’s story won him the prized pint glass and earned him a spot in the Lancaster Story Slam Grand Slam which will take place in November. Congratulations, Randy! Next up is Paul Armstrong with his story about the first time he realized that his way of seeing things wasn’t the only way to see things. Our final storyteller is Luanne Sims who in addition to being our emcee for the evening, shared about her first experience telling a story at a story slam. Our gratitude to LancLiving Realty, our 2020 sponsor. LancLiving Realty is a local real estate and property management firm based in downtown Lancaster, serving communities throughout Lancaster County, and focused on providing clients with ethical and knowledgeable service. Whether you are buying or selling, LancLiving agents focus on getting the best deal for you, the client.  LancLiving is proud to support great storytelling through the Lancaster Story Slam for the second year in a row.  LancLiving ... It's where you belong. If you enjoy our podcast, you will probably also enjoy our live virtual events! Our September Story Slam is themed “All Grown Up” and will be held at 7 pm on September 22nd. You can learn more details here.  Thanks for listening!

Welcome to the York Story Slam podcast, where we feature select stories from our monthly open mic storytelling events in York, Pennsylvania. On August 18th , eight storytellers shared their stories with our audience.  Our theme for the evening was BAD IDEA. We heard stories about defying death, encounters with law enforcement and wild animals, getting tattoos in questionable environments, and even one story about a guinea pig riding the family dog like a horse. In the end, our winner was reigning Grand Slam champion, Mina Edmondson, who told us about the time she took her four children on a spaceship to the moon. Mina earned a spot in our Grand Slam in November to defend her title! Next up is a story from Par Bowman, who told one of the cautionary tales she shares with her children — about how she got her second tattoo Our final story on this month’s podcast comes from Paul Armstrong. Paul shared the real story behind his mother's account of the time he and his brother took their Christmas wagon out for a spin. All the winners from this year’s open mic story slam events will return to compete for the title of Best Storyteller in York. Updates on our events are available on our website, and while you’re there, you can sign up for our monthly newsletter. You can also follow us on twitter , Facebook, and watch videos of all the stories from our events on our YouTube channel. Big thanks to our 2020 sponsor, KBG Injury Law, whose generous support is making this season possible. We hope to see you virtually or on stage soon! Thanks for listening.

Welcome to the York Story Slam podcast, where we feature select stories from our monthly open mic storytelling events in York, Pennsylvania. On July 21st, our theme for the evening was ROAD TRIP. We heard stories about teenage shenanigans, traveling in beat-up clunker automobiles, and sidekicks with names like Fry, Fish, and Foot.  In the end, we had a tie! Our first winning storyteller was Steph Holmes, who shared the story of a trip that helped her find her passion and path in life.  Steph earned a spot in our Grand Slam in November! Our second winner for the evening was Jamie Beth Cohen, who shared her story of the time she and her brother were in danger on a road trip.  Jamie Beth also earned a spot in our Grand Slam in November!  Our final story on this month’s podcast comes from Paul Armstrong. Paul remembered his own coming-of-age story from his senior year of high school. All the winners from this year’s open mic story slam events will return to compete for the title of Best Storyteller in York. Updates on our events are available on our website, and while you’re there, you can sign up for our monthly newsletter. You can also follow us on twitter , Facebook, and watch videos of all the stories from our events on our YouTube channel. Big thanks to our 2020 sponsor, KBG Injury Law, whose generous support is making this season possible.   We hope to see you virtually or on stage soon! Thanks for listening.

Welcome to the Lancaster Story Slam podcast! On our June 23rd Story Slam the theme was “Identity Crisis.” We heard seven stories from our wonderful storytellers. Our winner by audience vote for June’s Lancaster Story Slam was Paul Armstrong who shared his story of misjudging weeds and people.  Paul’s story won him the prized pint glass and earned him a spot in the Lancaster Story Slam Grand Slam which will take place in November. Congratulations, Paul! Next up is PK Hill who shares her story demonstrating that we are not the identity others assign to us. Our final storyteller on this month's podcast is Rebecca Thatcher Murcia who shared her story of coming to terms with her own biases. Our gratitude to our season sponsor LancLiving Realty. LancLiving Realty is a local real estate and property management firm based in downtown Lancaster, serving communities throughout Lancaster County, and focused on providing clients with ethical and knowledgeable service. Whether you are buying or selling, LancLiving agents focus on getting the best deal for you, the client.  LancLiving is proud to support great storytelling through the Lancaster Story Slam for the second year in a row!  LancLiving ... It's where you belong. If you enjoy our podcast, you will probably also enjoy our live virtual events! Our July Story Slam is themed “Gifts” and will be held at 7pm on July 28th. Register here! Thanks for listening!

Vanessa Guillen vanished from Fort Hood Army Base in Killeen, TX in 2020. (Update: Found deceased on 6/30/20) Steven Lombard and Paul Armstrong went missing from Merced, CA in 1993. Karen Wright vanished from San Felipe, Mexico in 2009. These cases remain unsolved.

Paul Armstrong is a consultant at eNthusaProve LLC. Their mission is to inspire you to lead your teams into claiming their entire goal-achieving potential, and to empower leaders who want to build on the very purpose of what it means to be human. Human-centered leadership is what they're all about.Top takeaways:- How to dominate your workplace and get inspired every day- Why other people must buy into your dreams- Being humble yet confident in the pursuit of excellenceEpisode Highlights:[00:00] Intro to Paul’s background[04:45] How to get people to buy into your dreams[06:25] Interpretation of the story of Genesis from the bible[07:25] Staying focus and not get confused as a leader[08:45] How to use the right tools for procurement[10:53] What can be done differently because of that extreme desire to want to delight the customer[12:42] Ways to become a leader in the industry[13:56] Understand your industry that it takes a different level of dedication[16:43] Skills needed to stay in your lane and be authentic.[21:46] Identifying what is your purpose for wanting to be a leader[27:15] Think deeply what kind of company do you want to be?[31:16] Creating value and outperform your competition[33:04] Find people with a technical specialty[40:29] Intrinsic vs extrinsic motivationStand-Out Quotes:"Many people are familiar with Genesis when God said, Adam, I'm going to give you dominion. If you look deeply into that word, dominion, it means to be the boss.""Understanding what it meant to improve a process and improve people's ability to create value and contribute to the purpose. And so while on the surface, it looked like process improvement. It was also a lot of just how do we get folks so that their talents are blossoming better and we're getting more fruit from each person."Connect:https://www.linkedin.com/in/paularmstrong/https://enthusaprove.com/

We've all got back problems and Vitamin D deficiency. But that's OK. Dr. Paul Armstrong is here. We love you. Love us back. Your mom probably told you that you can't buy friendship. We're saying she is wrong. Visit itsonlytwodollars.com and become a patron of the show. Absolve the latent guilt you've been carrying all these years. $5.00 friends gain access to a bonus feed of exclusive content. Aftershow topics, shenanigans, and awkward good nights can be yours. Support the show. Your conscience will be as clear as Paul's colon.

066 Extra Time & Penalties with Paul Armstrong by Mark Pitcher

Dr Carolyn Lam: Welcome to Circulation On The Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore. Dr Greg Hundley: And I'm Dr Greg Hundley, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Well, Carolyn, our feature article today looks at the use of Apixaban versus Warfarin, so a trial between the two in patients with atrial fibrillation and advanced kidney disease. But before we get to that, how about if we break away, grab a cup of coffee and go through some of the other important papers in this issue? Dr Carolyn Lam: Yeah, and why not start with talking about our gut and fiber in the diet. Now, we know that a diet poor in fiber is associated with the prevalence of hypertension, but what are the underlying mechanisms? Well, this first paper I want to talk about is from Dr Marques from Baker Heart and Diabetes Institute in Australia and colleagues who basically performed a nice series of mouse experiments and found that a diet lacking prebiotic fiber led to a gut microbiome that was pro hypertenenogenic facilitated the development of cardiac hypertrophy in germ free mice. Even in the absence of fiber, gut metabolites called short chain fatty acids usually produce from the fermentation of prebiotic fiber by the gut microbiota, but they were able to protect against the development of hypertension, cardiac hypertrophy and fibrosis in a preclinical model. This cardioprotection involved short chain fatty acid receptors, and a decrease in the ratio of sodium to potassium excretion and changes in genome white methylation that supported higher levels of T regulatory cells. Dr Greg Hundley: Oh my goodness, Carolyn. So I need to know what I eat for lunch? What's the take home message here? Dr Carolyn Lam: Lots of fiber and definitely not the low fiber westernized diet, which may underlie hypertension. And how? Through deficient short chain fatty acid production and thus the take home is maintaining a healthy, short chain fatty acid producing microbiome is important for the cardiovascular health. Dr Greg Hundley: Wow, Carolyn. I love that article because it really helps provide some perspective on all the diet information that we've been receiving lately. Well, my paper is from doctor ... another Carolyn, but this is Carolyn Ho from Brigham and Women's Hospital- Dr Carolyn Lam: I love her. Dr Greg Hundley: ... And it involves hypertrophic cardiomyopathy and left ventricular systolic dysfunction. So Carolyn, the term end-stage has been used to describe hypertrophic cardiomyopathy with left ventricular systolic dysfunction. And that's defined when someone has hypertrophic cardiomyopathy and the LVEF is less than 50%. The prognosis of patients with this condition has been reportedly poor, but it's very rare in occurrence and therefore, the natural history really remains incompletely characterized. So what did the authors do in this study? They evaluated more than 500 patients from 11 high volume hypertrophic cardiomyopathy specialty centers comprising the international Sarcomeric Human Cardiomyopathy Registry or SHaRe registry. And they were used to describe the natural history of patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction. Dr Carolyn Lam: Interesting. So what did they find, Greg? Dr Greg Hundley: Number one, first overall, this group of patients, hypertrophic cardiomyopathy with left ventricular systolic dysfunction occurs in about 8% of those with hypertrophic cardiomyopathy. Although the natural history of left ventricular systolic function and hypertrophic cardiomyopathy is variable, 75% of those that have this condition experience adverse events including 35% experiencing a death equivalent at a medium of 8.4 years after developing their systolic dysfunction. In addition to clinical features, the genetic substrate appears to play a role in both prognosis, so there are multiple sarcomeric variants, and in the risk for incident development of left ventricular systolic function with hypertrophic cardiomyopathy due to variance in the thin filaments within those myocytes. Dr Carolyn Lam: Nice. Thanks for that Greg. My next paper is a really interesting secondary analysis if you may, of the EXSCEL study. As a reminder, the Exenatide Study of Cardiovascular Event Lowering or EXSCEL assessed the impact of once weekly exenatide versus placebo in patients with type two diabetes and showed non-inferiority but not superiority for the primary MACE outcome. Now, during this trial, while aiming for glycemic echo-poise, a greater drop-in of open label glucose lowering medications occurred in the placebo group, thus prompting the current authors, which is Dr Rury Holman from University of Oxford and their colleagues to really explore the possible impact of unbalanced open labeled drop-in of glucose lowering medication on EXSCEL outcomes. To our modern diabetes trial, they used three methodologies. One, drop-in visit, right censoring. Two, inverse probability for treatment waiting. And three, applying drug class risk reductions. Now, Greg, I could either quiz you on these methods or summarize the results, which would you prefer? Dr Greg Hundley: Well, Carolyn, this calls for the infamous phone a friend. So one of the nice things we have at Circulation is a wonderful group of statisticians that really help us go through all the papers. But I sure would like to pick up the phone and call one of those folks now. But I think what I'm going to do ... maybe just give me the results of this study. That's what I prefer. Dr Carolyn Lam: I thought you might say that. So the EXSCEL observed has its ratios for MACE remained robust after right censoring or application of the literature derived risk reductions, but the exenatide versus placebo MACE effect size and statistical significance were increased by the inverse probability treatment waiting approach. So I think the take home is that effects of open label drop in cardioprotective medications do need to be considered carefully when designing, conducting and analyzing cardiovascular outcome trials of glucose lowering agents. Do we have the perfect solution? Perhaps not, but this was a really important paper to just look at and study. So Greg, I can see that you are stats out, so I'm going to tell you a little bit more about other papers in this week's issue. There's a research letter by Dr Zhang on transcription factor Kruppel-like factor 15 and how it regulates the circadian susceptibility to ischemia-reperfusion injury in the heart. Dr Greg Hundley: Very good, Carolyn. Well, I've got a couple of other papers. There's a nice in-depth piece from Dr Gregory Marcus from the University of California, San Francisco on how we evaluate and manage patients that have premature ventricular contractions. Dr Mori Krantz from Denver Health and Hospital Authority gives us an EKG challenge in someone that's had a needle stick. And then finally, there's a nice perspective piece from Dr Paul Armstrong from the Canadian VIGOUR Centre, department of medicine cardiology at the University of Alberta. And he really goes over nicely how we're going to do global collaboration to enhance cardiovascular care. What a great issue. And now onto that feature where we're going to hear a little bit about Apixaban and Warfarin in those individuals with atrial fibrillation and chronic kidney disease. Dr Carolyn Lam: Let's go, Greg. Today's feature paper really represents the first randomized data on NOAC versus warfarin in a very important group of patients, that is those with atrial fibrillation and advanced chronic kidney disease. So happy to have with us the corresponding author, Dr John Stanifer from Munson Healthcare, Traverse, Michigan. As well as our associate editor, Dr Chang-Sheng Ma from Beijing Anzhen Hospital in China. Welcome, welcome. So John, could you tell us the inspiration if you may, or the rationale, for doing this study? Dr John Stanifer: This is a population that's near and dear to my heart as a practicing nephrologist. We care for so many patients with atrial fibrillation, particularly those on dialysis or those with advanced kidney disease. And as other practitioners and people taking care of this population will tell you, this is just such a confusing and challenging clinical problem to try to deal with. And then really this stems from that important clinical need that we recognize almost on a daily basis. Dr Carolyn Lam: I just love that you shared that John, because coming from a nephrologist, and we're usually talking to cardiologists where we think about this all the time and have no idea what to do. So tell us about your study and what you found. Dr John Stanifer: As you know, these were data that were taken from the Aristotle trial that was finished in 2011, that was really a landmark study that established the real superiority of Apixaban compared with Warfarin and the general population. And it happened that within the study, there were several patients, 269 that had a creatinine clearance of between 25 and 30 milliliters per minute. We then took those data from those patients and compared really in this study, the safety of Apixaban compared with Warfarin within that subpopulation, and then compared that as an interaction with the safety of Apixaban versus Warfarin in patients with creatinine clearance of greater than 30. Dr Carolyn Lam: And what did you find? Dr John Stanifer: Well, in conclusion, we really found that among these patients with a creatine clearance of 25 to 30 MLs per minute in atrial fibrillation that Apixaban did cause less bleeding than Warfarin. And it appeared to be an even greater relative risk reduction when you compare that with the safety of Apixaban versus Warfarin and those with a less severe kidney disease. Dr Carolyn Lam: It's truly the first time I've seen data like this. So congratulations John and thank you so much for publishing this paper with us at Circulation. Chang-Sheng, Circulation seems to be publishing a lot in the space of combined renal and cardiac disease, which is very interesting. Why was this paper so important to us as well? Dr Changsheng Ma: It's a very important question for a clinical practice. The anticoagulation therapy in patient with advanced CKD. And observation or analysis have demonstrated inconsistent of findings regarding the net clinical benefit of warfarin in reducing the risk for stroke in patients with advanced CKD. The problem of Warfarin treatments in this patient group is dramatically higher bleeding risk. The current study also show that the bleeding risk was three- to four-fold higher in patient with advanced CKD compared to that in patient with creatinine clearance more than 30 milliliters per minute when treated with a Warfarin. So these studies are our first randomized data for NOAC compared with warfarin in patients with advanced CKD. The results provide important information as to the safety of Apixaban in this special patient group with high risk of bleeding. With reduced risk of bleeding, we may expect net clinical benefits of Apixaban in preventing stroke in patients with advanced CKD. Dr Carolyn Lam: Indeed. John, did you demonstrate that net clinical benefit or could you perhaps explain if future steps are needed to look at that a bit better? Dr John Stanifer: Well, I think absolutely future studies are needed. You have to keep in mind that these were pre-specified groups within Aristotle. These are still post-trial data from this study and that absolutely we need studies that are powered to really compare the safety. I would add not just apixaban with warfarin, but I would also add placebo to that. Dr Carolyn Lam: Interesting. Changsheng, you had some questions for John as well. Dr Changsheng Ma: Yes. John, I had questions for you. If you take a randomized trial for the answer for this question, how many cases do you think? Dr Carolyn Lam: How many cases of? Dr Changsheng Ma: How many cases should there be for a sample size for a trial? Dr John Stanifer: Well, you're really putting me on the spot here. I'll have to go back to my statistical days. Well, I think the easy part in the design of a trial for a question like this is that the event rates are so high. Whether that be for both safety outcomes related to hemorrhage and bleeding risks or primary benefit outcomes. So that would be very beneficial with that respect. But I think the key to designing a study ... and I know that there are several ongoing RENAL-AF and several others that are trying to examine this very question, but I think as a nephrologist, what we would kind of push back on a little bit is that there's no placebo arm to these trials. And I actually think that that would be a step forward even though that would be a very challenging thing, I think at this point to push for ... I think the nephrologist has kind of continued to push for that a little bit. Dr Carolyn Lam: So John, that was beautifully answered. If I could ask you then, have these results influenced your practice even now? Dr John Stanifer: Well, prior to this, we've been a little bit nervous with Apixaban, even though observational data may suggest that it would be safer or potentially usable in patients with advanced kidney disease. But part of the real conundrum and some of the challenges that come up are really around dosing of Apixaban. And they say, "Well, gosh, if they're in stage renal disease, yeah, maybe it's too bad. Maybe the kidney function is way too low and we need to kind of reduce it based just on that one criterion as opposed to the three criteria laid out in Aristotle." So I think that was some of the challenges. but I think after seeing these data and seeing the safety relative to Warfarin was really there in this patient group, yeah, it has influenced me a little bit. I am a little more adamant about switching patients. Dr Carolyn Lam: Yep. Chang-Sheng, do you agree with that? What do you think are next steps here? Dr Changsheng Ma: Because clinical practice is different, apparently, more evidence is badly needed to guide the future clinical practice because the patients with creatinine clearance even less than 25 milliliters per minute. And those in dialysis were not included in any of the pivotal studies of NOAC. Dr John Stanifer: Absolutely. Dr Changsheng Ma: It is still uncertain whether this patient will benefit from Apixaban or other NOACs. So in this study, even the significant less measured bleeding events were observed. I think the all-cause mortality was not different between the two groups. So the next step we should design a new trial to confirm whether Apixaban will really improve the prognosis of the patient with advanced CKD and AF. Dr John Stanifer: I will second that. For sure we want to answer that very important efficacy question related to this class of medications. Dr Carolyn Lam: Efficacy and patients on hemodialysis. Wow. This really just opens up a lot, but you're right. It's such tantalizing information that you see in ... so thank you so much John, for publishing this paper with us. Chang-Sheng, it's such a great paper. I remember the discussions we had during our editors’ discussions and it's so nice to see it out in print. I'm telling you, audience, you have to get hold of this paper. It will change this field I think and will lead to further trials exactly like you've heard here, and that we've put John on the spot to describe. Dr Carolyn Lam: Thank you very much gentlemen for a wonderful discussion. Thank you, audience, for joining us. You've been listening to Circulation On The Run. Join us again next week. Dr Greg Hundley: This program is copyright the American Heart Association, 2020.  

This week I got the chance to interview Paul Armstrong. Paul and I go back some time to when I was working for a large corporate and he came in to bid on some work. He was referred via a network connection and was amazing at identifying the needs of the business as well as working out a plan of attack for building out a global digital presence for the company I was working for. While the work did not go ahead, I was able to maintain contact over the years following this. And as my life changed, I reached out to Paul for some mentorship in my next steps. He was more than happy to oblige. That being said, Paul was always happy to meet up, have a beer and hear what was going on. Often times it was a random encounter that lead to rekindling our meet ups but each and every time Paul met up with me with genuine enthusiasm. Keen to hear where I was at and what I was thinking. A true man of the people! Links for Mental Health in Australia:Beyond Blue -  1300 22 4636Open Arms - 1800 011 046Kids Helpline - 1800 55 1800Lifeline - 13 11 14MensLine Australia - 1300 78 99 78Suicide Call Back Service - 1300 659 467 Thanks everyone for listening! I am keen to get questions from you so that I can adjust and do more with the show. So you can reach out to me via email (podcast@unplugyourself.net) Instagram (@unplug_your_self]) or twitter (@unplugyour_self). I’d really like to hear what you think, topics you want covered and if that’s not your bag, just some general feedback. Also make sure you go to iTunes and give the show some stars and feedback. It all helps.Just remember, by leveraging your self awareness, managing your mindset, having mindfulness and building your emotional intelligence you can unlock your negativity and be the person you want to be!

This week, Sue and I get into career transition.  Nic talks to Paul Armstrong, a leading career transition from Inner Sanctum Consulting, an expert who has had his own experience with career transition answers all the questions we have about "what's next"?  He challenges us to think more broadly about our skill set.  Nurses are pretty amazing creatures and we possess skills that we take for granted that other industries invest years and thousands of professional development dollars in growing in their own employees.  Nurses can inherently think laterally: linear thinking is not useful when we're presented with a patient load - we must triage, prioritise and time manage appropriately.  We innately know how to manage high pressure situations: how many professionals come to work with life and death situations ever at our periphery.  Nurses must be comfortable with the fact that any one of their patients may arrest out of the blue.  We know communication: we talk to all manner of people everyday - we might be nursing the homeless guy in Room 3 and the CEO of a large multinational company in Room 4: that takes skill.  So Paul walks us through seeing our skill set as transferrable, as opposed to clinically subspecialised.

On this episode of Good Nerd Bad Nerd, I talk Sam and Keiley Spear, the two sisters responsible for the new science fiction short film "CC". They tell us all about making this short film and how our the rapidly changing technology influence the tone of the film. They also talk about the grey areas that this technology starts to enter without safe guards. CC Logline In this suspenseful sci-fi, an AID (Artificially Intelligent Device) by the name of CC, has been leased by a nanny agency to Lena to help care for her daughter. When a violent incident occurs between CC and Lena, an investigative team is tasked with determining exactly what happened. Credits CC: Jewel Staite Lena Howard: Sharon Taylor Adelaide Howard: Audrey Wise Alvarez Erin: Susan Hogan Director: Kailey Spear and Sam Spear Screenplay: Kailey Spear and Sam Spear Producer: Natasha Wehn, Lauren Beason, Victoria Burkhart, Paul Armstrong, Alicia Bernbaum, Stephanie Halber, Ingo Lou ABOUT DUST DUST, a division of global content studio Gunpowder & Sky, is the first premium sci-fi entertainment brand that reaches fans across all platforms, giving voice to both emerging and established filmmakers. DUST presents thought-provoking science fiction content, exploring the future of humanity through the lens of science and technology. From timeless classics to cutting-edge movies, series, short films, and podcasts, DUST acquires, produces and distributes all content types. In 2018, DUST released the Zach Strauss directed short film Bad Peter at Tribeca - a cautionary tale about an overbearing AI assistant - starring Golden-Globe nominee Frankie Shaw ("SMILF"). DUST also premiered the feature film PROSPECT starring Pedro Pascal (“Narcos”, “Game of Thrones”, Equalizer 2), which recently debuted in the U.S. on Hulu, and internationally on Netflix. In 2019, DUST released ZERO, a post-apocalyptic story of survival and hope, directed by the Brothers Lynch and starring Bella Ramsey (“Game of Thrones”). With more than 15M monthly uniques, DUST operates its own channels that are available on multiple platforms including YouTube, Facebook, VRV, Pluto, Xumo, Samsung Plus, Sincalir’s STIRR, Sinclair’s TBD, NBC Watchback, and Vizio. Through its partnership with USC’s School of Cinematic Arts, DUST premiered the George Lucas 1967 short film, “Electronic Labyrinth: THX 1138 4EB”, followed by premieres of legendary filmmaker Robert Zemeckis’ 1972 student short film “The Lift” and ‘Star Wars: The Last Jedi” filmmaker Rian Johnson’s student short film “Evil Demon Golf Ball From Hell”. DUST also hosts podcasts and special events such as “The Future Is Female” screening that celebrates female sci-fi directors in film, as well as 'Represent: Diversity in Sci-Fi', an art show and panel celebrating and examining multicultural voices in the sci-fi genre. On August 18th, 2018, DUST launched DUSTx on Roku, a new sci-fi channel featuring timeless movies such as A Scanner Darkly, Bill & Ted's Excellent Adventure, Star Trek: First Generation, Paycheck, and The Running Man, as well as series such as “Mystery Science Theater 3000”, “Ray Bradbury's Science Theater”, “Beyond Westworld”, and the original “Roswell”; in addition, DUST 500+ short films by the talent of tomorrow, including Rise, Jonah, and Automata. On August 19th, 2019, DUST launched the DUSTx mobile app on both iOS and Android, with a launch on AppleTV soon to follow.

On this episode of Good Nerd Bad Nerd, I talk Sam and Keiley Spear, the two sisters responsible for the new science fiction short film "CC". They tell us all about making this short film and how our the rapidly changing technology influence the tone of the film. They also talk about the grey areas that this technology starts to enter without safe guards. CC Logline In this suspenseful sci-fi, an AID (Artificially Intelligent Device) by the name of CC, has been leased by a nanny agency to Lena to help care for her daughter. When a violent incident occurs between CC and Lena, an investigative team is tasked with determining exactly what happened. Credits CC: Jewel Staite Lena Howard: Sharon Taylor Adelaide Howard: Audrey Wise Alvarez Erin: Susan Hogan Director: Kailey Spear and Sam Spear Screenplay: Kailey Spear and Sam Spear Producer: Natasha Wehn, Lauren Beason, Victoria Burkhart, Paul Armstrong, Alicia Bernbaum, Stephanie Halber, Ingo Lou ABOUT DUST DUST, a division of global content studio Gunpowder & Sky, is the first premium sci-fi entertainment brand that reaches fans across all platforms, giving voice to both emerging and established filmmakers. DUST presents thought-provoking science fiction content, exploring the future of humanity through the lens of science and technology. From timeless classics to cutting-edge movies, series, short films, and podcasts, DUST acquires, produces and distributes all content types. In 2018, DUST released the Zach Strauss directed short film Bad Peter at Tribeca - a cautionary tale about an overbearing AI assistant - starring Golden-Globe nominee Frankie Shaw ("SMILF"). DUST also premiered the feature film PROSPECT starring Pedro Pascal (“Narcos”, “Game of Thrones”, Equalizer 2), which recently debuted in the U.S. on Hulu, and internationally on Netflix. In 2019, DUST released ZERO, a post-apocalyptic story of survival and hope, directed by the Brothers Lynch and starring Bella Ramsey (“Game of Thrones”). With more than 15M monthly uniques, DUST operates its own channels that are available on multiple platforms including YouTube, Facebook, VRV, Pluto, Xumo, Samsung Plus, Sincalir’s STIRR, Sinclair’s TBD, NBC Watchback, and Vizio. Through its partnership with USC’s School of Cinematic Arts, DUST premiered the George Lucas 1967 short film, “Electronic Labyrinth: THX 1138 4EB”, followed by premieres of legendary filmmaker Robert Zemeckis’ 1972 student short film “The Lift” and ‘Star Wars: The Last Jedi” filmmaker Rian Johnson’s student short film “Evil Demon Golf Ball From Hell”. DUST also hosts podcasts and special events such as “The Future Is Female” screening that celebrates female sci-fi directors in film, as well as 'Represent: Diversity in Sci-Fi', an art show and panel celebrating and examining multicultural voices in the sci-fi genre. On August 18th, 2018, DUST launched DUSTx on Roku, a new sci-fi channel featuring timeless movies such as A Scanner Darkly, Bill & Ted's Excellent Adventure, Star Trek: First Generation, Paycheck, and The Running Man, as well as series such as “Mystery Science Theater 3000”, “Ray Bradbury's Science Theater”, “Beyond Westworld”, and the original “Roswell”; in addition, DUST 500+ short films by the talent of tomorrow, including Rise, Jonah, and Automata. On August 19th, 2019, DUST launched the DUSTx mobile app on both iOS and Android, with a launch on AppleTV soon to follow.

On this week’s show, Chris speaks with Mike Ames about Mike’s approach to networking. We also catch up with Paul Armstrong about the forthcoming TBD Conference in December. The first 10 WB-40 listeners can get a £600 for just £100 if you follow this link.

Paul Armstrong has a long history in providing ICT consultancy to organisations in New Zealand and further afar with a long and illustrious career at Synergy/Fronde - but that's all history now!Paul takes us through the ups and downs of his career, and how he is excited again to be at TipoTapp bringing the cloud unicorns to all those that need to both move and develop upon the major cloud services out there.For those that need to sell (and let's be honest, who doesn't) Paul has a fascinating series of insights alongside hints & tips for us all.- https://nz.linkedin.com/in/tgz-paul-armstrong- https://www.tipotapp.com/------------------------------------------------------Behind the scenes of tech, media, and startups, hosted by Mike Riversdale, Raj Khushal, Vivian Chandra, and others. See you at #WellyTechShare, Follow and Like us on:- https://twitter.com/AccessGrantedNZ - https://facebook.com/AccessGrantedNZ - https://linkedin.com/company/access-granted-podcast - https://nstagram.com/accessgrantednz/ Subscribe to the show:- https://www.accessgranted.nz/subscribe/#WellyTech news and events- https://wellytech.accessgranted.nz/- https://www.meetup.com/WellyTech/- https://mobile.twitter.com/wellytechnz Buy the AG merch:- https://www.accessgranted.nz/shop/

Vancouver is saturated with film on the second week of August: Vancouver Chinese Film Festival, Vancouver International Youth Film Festival and more with Christine Song and Paul Armstrong!

Vancouver is saturated with film on the second week of August: Vancouver Chinese Film Festival, Vancouver International Youth Film Festival and more with Christine Song and Paul Armstrong!

Brandon and Paul share the stories, programs and initiatives of the awaited Vancouver International Youth Film Festival & Vancouver Chinese Film Festival!

Brandon and Paul share the stories, programs and initiatives of the awaited Vancouver International Youth Film Festival & Vancouver Chinese Film Festival!

“A Low-Cost Automated System for High-Throughput Phenotyping of Single Oat Seeds” with James Clohessy. A Rube Goldberg machine is a machine intentionally designed to complete a simple task using overly complicated steps. James Clohessy and his team are doing just the opposite. Using machine learning, web cameras, open software, and photogrammetry techniques, they’re developing low cost, high-throughput, high efficiency phenotyping systems. With these systems, researchers can save hours of time that would normally be spent on taking individual seed measurements by hand, such as height, width, and color, all while gaining greater detail about the seed such as volume and density. Listen in to learn more about James’ new system as well as: What are phenotyping and photogrammetry? What are some of the applications of knowing seed size, color, and weight? What are some of the limitations of high-throughput phenotyping? What are some of the future applications of these machine learning systems? If you would like more information about this topic, this episode’s paper is available here: dx.doi.org/10.2135/tppj2018.07.0005 This paper is always freely available. If you would like to find transcripts for this episode or sign up for our newsletter, please visit our website: https://dl.sciencesocieties.org/publications/podcast Contact us at podcast@sciencesocieties.org or on Twitter @FieldLabEarth if you have comments, questions, or suggestions for show topics, and if you want more content like this don’t forget to subscribe. If you would like to reach out to James, you can find him here: jameswclohessy@gmail.com https://www.linkedin.com/in/jameswclohessy/ @ufifasnfrec Resources Cornell Plant Breeding and Genetics Section: https://plbrgen.cals.cornell.edu/ Paul Armstrong: https://www.ars.usda.gov/plains-area/mhk/cgahr/spieru/people/paul-armstrong/ Dr. Guo’s Easy PPC program: http://park.itc.u-tokyo.ac.jp/Field-Phenomics/ninolab/PhenotypingTools/EasyPCC.html HeatSync Labs: https://www.heatsynclabs.org/ Field, Lab, Earth is copyrighted to the American Society of Agronomy, Crop Science Society of America, and Soil Science Society of America.

1992 didn't just see the birth of the Premier League and Champions League but it saw the return of Match of the Day to our TV screens for the first time in four years. On this latest episode we get the inside track on MOTD in the 90s, as Ash and Joel are joined by former editor on the show Paul Armstrong. The boys chat through football coverage in the 1990s, Des Lynam, Motty vs. Barry and even bear hugs with David Ginola. Plus there's Lineker, Gubba, Brooking and lots of 'You don't win anything with kids' too. So sit back and enjoy our look back at Match of the Day in the 90s! Paul's new book detailing his career on the show and football at the BBC 'Why Are We Always On Last' is out now. Find us online at http://www.ak90s.co.uk on twitter https://www.twitter.com/AK90s and facebook https://www.facebook.com/ak90s

Timeline: 7:21 Are the commentators at the game? 12:53 Refereeing decisions on MOTD 21:10 The future of highlights shows 28:50 MOTD Nostalgia 37:30 Female pundits 41:49 How MOTD gets made Our guests today are Steve Wilson, Guy Mowbury and Paul Armstrong. Wilson and Mowbray are some of the finest commentators on television and regularly appear on MOTD. Armstrong was BBC Match of the Day's editor for 14 years. If you enjoy the episode and want to go deep on MOTD I recommend you buy Why Are We Always On Last? which is the autobiography of Paul Armstrong. You can buy Why Are We Always On Last? on Amazon or wherever you get your books. In the episode we discuss: the future of broadcasting & MOTD, how MOTD is made, the 3 pm blackout and a whole lot more. If you're American and wondering what Match of the Day is, it's a show based on highlights and analysis, like Sunday Night Countdown or Baseball Tonight. Except it is 90 minutes and has no commercials. It's an essential part of British football culture and tradition. And as this is the first time having 3 people I mistakenly never asked them to introduce themselves with their voice. The first person you'll hear from is Guy Mowbury. The next voice is Steve Wilson. And the other voice is Paul Armstrong.

ON PAUL: a leading strategist, author and speaker on the future of technology, disruption anything and everything to do with future. He runs the technology advisory HERE/FORTH where he helps clients including PwC, Coca-Cola, O2 and more to understand trends and how to sensibly apply emerging technologies strategically. This smart cookie currently writes for a number of publications, including Forbes, Reuters, Cool Hunting, Evening Standard and Short List. He also wrote a book: ‘Disruptive Technologies’, and launched TNN (The New Normal) which we help with: a private community and online resource/hub (powered by Slack) on all things future, with amazing speakers each month. More on Paul here.WHY PAUL: you want to know him, talk to him, get him a coffee. He's a smart cookie, works fast, delivers faster. Says as it is, doesn't sugarcoat it. He talks extremely fast, so you better have an espresso when talking to Paul. He's also a good egg and funnier than he thinks. It's a pleasure to have him as our first guest. ““BEST BUSINESS ADVICE YOU GOT:- MAKE IT SIMPLE.””

In the first episode of Back to Ones podcast, we chat with Paul Armstrong, an independent film producer, about: • How to have the best shot at getting into the Crazy8s independent film competition • Tips on getting started in filmmaking • And, where he sees Canadian film trends going Come along for the ride with us!

Dr Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore. This week features Circulation Global Rounds, a brand-new series of papers from all across the world that you are going to want to hear about, coming right up after these summaries. The first original paper this week tells us that community trends and acute decompensated heart failure may differ by race and sex. Dr Patricia Chang from University of North Carolina in Chapel Hill and colleagues examine the 10-year rates and trends of hospitalized acute decompensated heart failure in the Atherosclerosis Risk in Communities or ARIC study, which sampled heart failure–related hospitalizations in four US communities from 2005 to 2014, using ICD-9 codes. They found that acute heart failure with reduced ejection fraction was more common in black men and white men, whereas acute heart failure with preserved ejection fraction was most common in white women. Rates of hospitalized acute decompensated heart failure increased over time, with higher rates in blacks, and rising cases of preserved ejection fraction heart failure. Mortality rates were 30% at one year with a more pronounced decrease over time in blacks but generally did not differ by heart failure types. Whether racial differences may be related to age of onset comorbidities, or other community level and social economic factors, deserve further study. The next paper is a population-based study identifying long-term outcomes and risk factors and children with hypertrophic cardiomyopathy. Dr Alexander from Boston Children's Hospital and colleagues examine the National Australian Childhood Cardiomyopathy Study, a long-term national cohort study with a median follow-up duration of 15 years. They found that the greatest risk of death or transplantation for children with hypertrophic cardiomyopathy was in the first year after diagnosis, with 14% of patients achieving this combined end point compared to 0.4% per year thereafter. Risk factors for death or transplantation included symmetric left ventricular hypertrophy at diagnosis, Noonan syndrome, increasing left ventricular free wall thickness, and lower fractional shortening during follow up. The majority of surviving patients had no symptoms. Thus, children with hypertrophic cardiomyopathy who are alive one year after diagnosis have a low long-term rate of death or transplantation. Deaths from heart failure usually occur soon after diagnosis, whereas the risk of sudden cardiac death is ongoing. The next paper is the first demonstration of a peripheral clock in the perivascular adipose tissue that could contribute to the homeostatic regulation of circadian blood pressure variation. Co-corresponding authors Dr Chang and Chen from University of Michigan and their colleagues used a novel brown adipose specific aryl hydrocarbon receptor, nuclear translocator-like protein 1 or Bmal1 and angiotensinogen knockout mouse model to demonstrate that local Bmal1 in perivascular adipose tissue regulated angiotensinogen expression and the ensuing increase in angiotensin II, which acted on smooth muscle cells in the vessel walls to regulate basal activity and blood pressure in a circadian fashion during the resting phase. In fact, deletion of Bmal1 or angiotensinogen in the perivascular adipose tissue resulted in a superdipper phenotype with exacerbated hypotension during the resting phase. These findings imply that it is possible that obesity could alter the perivascular adipose tissue peripheral clock, thus promoting abnormal dipper phenotypes and increasing cardiovascular risk. The results therefore inform the design of novel therapeutic approaches for hypertension by targeting the perivascular adipose tissue peripheral clock. What is the net clinical benefit of oral anticoagulation for very elderly patients with atrial fibrillation? Well, the next paper by first author Dr Chao, cocorresponding authors, Dr Chen from Taipei Veterans General Hospital and Dr Lip from University of Birmingham, addresses this question. These authors use a nationwide cohorts study in Taiwan to compare the risks of ischemic stroke and intercerebral hemorrhage between patients with and without atrial fibrillation, all aged 90 years and above, from 1996 to 2011, and they also compared patients treated with warfarin and non-vitamin K antagonists oral anticoagulants, or NOX from 2012 to 2015 when NOX were available in Taiwan. They found that even among these very elderly patients aged 90 years and above, atrial fibrillation was associated with an increased risk of ischemic stroke compared to patients without atrial fibrillation. Warfarin use was associated with a lower risk of ischemic stroke, with no difference in intercerebral hemorrhage risk compared to nonwarfarin treatment. The use of warfarin was associated with a positive net clinical benefit compared to being untreated or to antiplatelet therapy. Compared to warfarin, NOX were associated with a lower risk of intracerebral hemorrhage, with no difference in the risk of ischemic stroke. Thus, oral anticoagulation may still be considered for thromboprophylaxis in very elderly patients with atrial fibrillation, with NOX being a favorable choice The final paper provides insights into the mechanisms linking obesity and cardiovascular diseases. Co-corresponding authors, Dr Kong and Wang from Peking University Health Science Center and colleagues use a combination of animal models and human adipose biopsies to characterize a new adipokine named family with sequence similarity 19, member A5 or FAM19A5. This novel adipokine was capable of inhibiting post injury neointoma information via sphingosine-1-phosphate receptor 2 and downstream G12/13-RhoA signaling. Thus, down regulation of FAM19A5 during obesity and loss of its vascular protective function may trigger cardiometabolic diseases. Well, that wraps it up for our summaries. Now for our feature discussion. I'm just so excited about today's feature discussion, because we're talking about Circulation going global. And I am just absolutely delighted to have with us, our Editor-in-Chief himself, Dr Joe Hill from UT Southwestern, as well as our Senior Advisory Editor, Dr Paul Armstrong from University of Alberta. So Joe, could you start by telling us a little bit more about your vision for the global outreach of Circulation? Dr Joe Hill: Thank you, Carolyn. As I hope our readers are aware, Circulation is a global journal with a global footprint. We have editors distributed around the world in 16 countries and 10 time zones. And importantly, those editors all have an equivalent role at the leadership table. Part of the reason for this is because cardiovascular disease is now, as we are all aware, a global scourge. There are no more final frontiers for cardiovascular disease. That said, the manifestations of cardiovascular disease differ in different parts of the world. In the developed world, and the developing world, for example, the way cardiovascular disease manifests itself can be very different. And at the same time, the way in which the disorders are tackled are different. The way we tackle heart disease in the West can be different than it is in the East, for example. And there are important initiatives that have emerged in different pockets of the world, best practices that we need to understand better. What can we all learn from the way in which cardiovascular disease manifests itself around the world and it's being addressed around the world? Dr Carolyn Lam: Joe, you had me at hello. I remember that when you first took over as Editor-in - Chief and I heard you say this, I was just floored, because coming from Singapore and all our listeners out there in Japan and China, we just really appreciate that global outlook. So thank you, on behalf of us all. Tell us a bit more about this new initiative then for the journal. Dr Joe Hill: I will tell you in broad strokes, that Paul Armstrong, a noted clinical trial is from Canada, who is a household name in the cardiovascular world, he and I cooked up a scheme that Paul will describe, where we will reach out on a regular basis for insights from various different countries, ultimately, circling the globe progressively over time. And I will defer to Paul to tell us more about the specifics. Dr Paul Armstrong: Carolyn, it's an exciting initiative and as someone a little long in the tooth, but still believing that you can teach an old dog new tricks, I would point out that Circulation is almost 70 years old, and it has staying power. And one of the reasons that it has staying power is because it is capable of reinventing itself, and so I was attracted to help out again, from the editorial process, given Joe's vision and leadership and the excitement around the reinvention that you've described, to get involved with this initiative. And I was inspired, of course, by the fact that those of us who do clinical trials appreciate that a lot of different ideas, a lot of different cultures and perspectives are brought to a collaborative table. And I'm thinking back now, Carolyn to three years ago, when you and I first met enjoying courses as part of a trial in heart failure, which involves 43 countries, 800 sites, it will be 5000 patients centers, we've traveled separately and together around the world, convincing people that there are unmet needs in heart failure and other parts of cardiovascular disease, we learned that the approach to standard of care, the rigor which is applied, the exquisite sensitivities around differences that are meaningful, and the tricks that some investigators and countries use that we can all I think, learn from has been very revealing. So I think in this initiative, we want to have thought leaders. And we've already I think, commenced and have two outstanding leaders from Japan and India to come forward in the first two quarters of this initiative. Tell us about the regional epidemiologic features, cardiovascular disease in their regions, what the most important challenges are, what their best practices are, that you're alluded to, who provides cardiovascular care and what the impediments are to progressing because we think if we listen and learn as essentially knowledge brokers, because welcome to Circulation, we can facilitate raising the level of all of the boats in the water and potentially make new partnerships and do a better job. So I'm excited about this. I'm delighted that Joe was receptive and really look forward to working with him and some of these terrific people around the world, you included who brings such a unique and important perspective from which we can all learn. Dr Carolyn Lam: Oh, I love that so much Paul. Thanks for putting it that way. International knowledge brokers, that's what we hope to be. Isn't that fabulous, just an opportunity to learn from each other, everybody having stuff to bring to the table? Tell us a bit more though, what are you looking for in these papers? Dr Paul Armstrong: We have some guidelines. But as Joe insists we're not going to be formulaic. We're going to allow diversity of approaches. We're going to invite a thought leader and hope that that thought leader might invite one or two others, we want to limit it to three co-authors. We want obviously some insights into how cardiovascular health professionals are being trained, what research infrastructure exists, and how they access the literature, how do they read Circulation, how do they read other journals, and are there collaborative ideas that they've developed to their neighbors to the East and West that may be could be broadened? Are there unmet needs that they've indicated similar or different from those in Western Europe, South America? We've got about seven or eight points of light that we hope to illuminate in the course of this exercise. And the prospectus that's laid out in an editorial that Joe and I collaborated on that I believe, Joe, is going to come out in early July. Dr Joe Hill: That's exactly right, Paul. And I would just echo exactly what you said that just the opposite of a formulaic, cookie cutter approach. We want to leverage the beautiful diversity of our world. The different approaches that people take to attack this scourge that is keeping a humble approach to tackle instead of the visas that is humbling bar none. There is nothing that is more globally important than the continued growth and expansion of cardiovascular disease. And importantly, we can all learn from each other. There are exciting initiatives that I've learned about in South America and in pockets of Europe and in Asia, and in the Middle East that we can all benefit from, and we want to shine a bright light on that. These pieces will be relatively short. They will be in our Frame of Reference section, so 1200 words or so, so that they are accessible so that people, you know, feel that they can carve out, you know, four minutes in their busy day to read what cardiovascular disease looks like, as Paul said, our first ones will be from Japan and India, and we plan to reach out to South America and to the Middle East, and just continue on around until over the course of the next number of years, we've touched virtually every country in the world. Dr Carolyn Lam: And that's huge. And are there any specific types of cardiovascular disease that you might be looking to focus on? Dr Joe Hill: You know, I don't think so. One of the points that I have made and learned is that in the West, in the developed world, cardiovascular disease increasingly has become a chronic disorder where more and more people, over the course of the last six years are surviving their acute coronary syndrome, their tachyarrhythmia events, and they are developing chronic disorders like heart failure, whereas in the East, it is the atherothrombotic manifestations that have both MI and stroke that are expanding rapidly. So given that the face of cardiovascular disease is different in different parts of the world, different strategies have to be leveraged to address that, and we want to learn about that. Dr Carolyn Lam: I would love to have you both come talk again, when we receive some of these papers and just reflect on the things that we're learning. Paul, did you have anything else that you wanted to add? Dr Paul Armstrong: I think, Carolyn that hits the high spots. I suppose we should mention diabetes and obesity and the expanding epidemic that seems to effect some regions such as India, in the Middle East, even more than other areas, but I think this is going to be great. We're gonna have some fun and learn and exciting and hopefully it will catalyze better care and better thinking around this enemy that we all face. Dr Carolyn Lam: Listeners. You heard it right here, Circulation on the Run. I'm sure you're excited as I am about this. You have to read the editorial. It's a fantastic read. Thanks for joining us today. And don't forget to tune in again next week.

“Good Times” from June 3, 2018 by Paul Armstrong. The post Good Times appeared first on Cornerstone: A Transforming Community.

This episode of SKUFood Talks is with Paul Armstrong, President of AMCA sales & marketing. Paul has great experience as a food broker and we challenge him to help us understand where the food industry is going in the future. We discuss:The future retail landscapeBranded products and where they are goingControl label products and where they are goingDecision making at retailers in the futureProducts and categories that have opportunities in the futureThe role of food brokers in the future See acast.com/privacy for privacy and opt-out information.

This episode of SKUFood Talks is with Paul Armstrong, President of AMCA sales & marketing. Paul has great experience as a food broker and he shares some insights into what brokers do and how to develop mutually beneficial relationships that get more products in the shopping cart.We discuss:The role of a food brokerHow the role of food brokers has evolvedFinding a food brokerDeveloping the relationship between the supplier and food brokerFees for food brokersRetail coverageThe ideal principal or supplierMaximizing the value from food brokers See acast.com/privacy for privacy and opt-out information.

On this week’s show we interview Paul Armstrong about his book Disruptive Technologies, and his new venture #TNN Matt’s Yang this week is the wonderful ifootpath.com. If you can bear it, the Yin is here. If you want to continue the conversation, you can do so over on our WhatsApp group – http://bit.ly/WB40WhatsApp

Today on the Perception Podcast we welcome Paul Armstrong. Paul is a leading strategist, author and speaker on the future of technology, disruption, retail innovation, media industry, social technologies, consumer technology, mobile innovation, IoT, Martech/Adtech, start-ups and the start-up ecosystem. He runs the technology advisory HERE/FORTH where he helps clients including PwC, Coca-Cola, O2, P&G, jkrGlobal and MEC understand trends and how to sensibly apply emerging technologies strategically. Paul's first book, ‘Disruptive Technologies', offers organizations a distinct response to emerging technologies including Blockchain (Bitcoin), artificial intelligence, graphene and nanotechnology and other external factors - such as the sharing economy, mobile penetration, millennial workforce, ageing populations - that impact on their business, client service and product model. Lets get to it.

Crazy 8s Event, Theatre and Film smashed all together with 2001 A Space Odyssey's soundtrack!

Crazy 8s Event, Theatre and Film smashed all together with 2001 A Space Odyssey's soundtrack!

We all know that technology is evolving at a rapid rate, and it's changing the way we live. Do you call a cab, or do you use Uber? Do you stay in a hotel, or do you check Airbnb? Do you read a book or a Kindle? These products and services quickly enter our world and become the norm. But just knowing that technology is evolving is not enough, you need to understand how it is impacting you and how you can evaluate what industry will be disrupted next.This week on the show we interview an expert who can help you understand, evaluate, and respond to disruptive technologies that are sure to have a big impact on your business and your life. (Bitcoin anyone?) Our guest this week is Paul Armstrong. Paul is a leading strategist, author and speaker on the future of technology, disruption, retail innovation, media industry, social technologies, and more. Paul runs the technology advisory HERE/FORTH where he helps clients understand trends and how to sensibly apply emerging technologies strategically.Paul is regularly seen on the BBC and News at Ten, when industry comment is called for, and currently writes for a number of publications, including Forbes, Cool Hunting and Short List. Paul's first book, Disruptive Technologies: Understand, Evaluate, Respond, offers organizations a distinct response to emerging technologies including Blockchain (Bitcoin), artificial intelligence, and other external factors - such as the sharing economy, mobile penetration, millennial workforce, aging populations - that impact on their business, client service and product model.

Paul Armstrong founder of Here/Forth joins the Movidiam Podcast. The digital marketer, strategist and technology advisor shares with us his personal journey along with insight on rapidly changing and emerging technologies.

Paul Armstrong founder of Here/Forth joins the Movidiam Podcast. The digital marketer, strategist and technology advisor shares with us his personal journey along with insight on rapidly changing and emerging technologies.

In this episode, Leon and Justin sit down with Jan Miksovsky and Rob Bearman of of the recently released Elix Project. Elix is a community-driven collection of high-quality web components for common user interface patterns such as lists, menus, dialogs, carousels, and so on. The modular nature of web components let you easily incorporate them into your web apps, and their standard definition ensures good results across all mainstream browsers. Resources https://elix.org/ https://github.com/elix/elix Around the Web in Two Minutes Preact 8.0 Beta Release https://github.com/developit/preact/releases/tag/8.0.0 Apple updates Safari Technology Preview to Release 27 with Web Inspector updates https://9to5mac.com/2017/04/05/safari-technology-preview-release-27/ Firefox Will Add a Settings Section That Lets You Control "Performance" https://www.bleepingcomputer.com/news/software/firefox-will-add-a-settings-section-that-lets-you-control-performance-/ Google Chrome update should prevent webpages skipping back to the top as you scroll farther down the page as it progressively loads new content http://www.theverge.com/2017/4/11/15260994/google-chrome-update-fixes-page-jumps-scroll-anchoring Work continues to bring the certificate viewer link back into Chrome's Page info window, with a code review ongoing for the update hopefully landing in M59. https://codereview.chromium.org/2737413004/ https://bugs.chromium.org/p/chromium/issues/detail?id=663971#c64 Twitter has been writing a series of informational posts on their path to Twitter Lite, a progressive web app at scale. One of the posts this week from Paul Armstrong dives into high performance and React: https://medium.com/@paularmstrong/twitter-lite-and-high-performance-react-progressive-web-apps-at-scale-d28a00e780a3 Microsoft Edge 15 has shipped to stable and brings a host of new features including Payment Request API, Brotli compression support, WebRTC v1, and CSS Custom Properties (among many more) https://blogs.windows.com/msedgedev/2017/04/11/introducing-edgehtml-15/#khMRm5zgmPDmllbl.97 https://www.pwastats.com/ is a new a community-driven list of stats and news around Progressive Web Apps and their ability to be better for end users. Guests Rob Bearman (@robbearman) Jan Miksovsky (@JanMiksovsky) Panel Leon Revill (@RevillWeb) Justin Ribeiro (@justinribeiro)        

The Bill Kelly Show Live at  Mohawk College & Mohawk Partnership Guest Speakers: Peter Kranendonk, President (Walters) Paul Armstrong, Vice-President, Academic (Mohawk)

Paul Armstrong (my husband!) writes software at Twitter, races bikes, is obsessed with cats, and is constantly working to perfect his vegan donut recipe. He's also the very best person I know, but hey, I'm biased

Paul Armstrong (my husband!) writes software at Twitter, races bikes, is obsessed with cats, and is constantly working to perfect his vegan donut recipe. He's also the very best person I know, but hey, I'm biased

This week Michelle Fern talks to Paul Armstrong, founder of earthbath about their new dental wipes. earthbath Tooth and Gum Wipes are the easy and convenient solution to keeping your pet’s mouth clean from plaque, tartar and odor-causing bacteria. Their totally natural formula is free of parabens, alcohol, and other nasties that don’t belong in your pet’s mouth. Use daily for best results. Questions or Comments? Send them to: michelle@petliferadio.com. More details on this episode MP3 Podcast - Earthbath Dental Wipes with Michelle Fern

In this week's episode Michelle Fern welcomes Paul Armstrong, President and CEO of Earthbath. From the beginning, earthbath has been developed and manufactured in California with only the safest, finest ingredients from nature. In the second segment, Michelle talks to Fred Silber, President of Enchanted Home Pet, makers of the TheraCool Cooling Gel Pad. Born from the determination to develop the highest quality and most innovative products, Enchanted Home Pet’s attention to detail, design and functionality is unmatched by any pet products anywhere. Questions or Comments? Send them to: michelle@petliferadio.com. More details on this episode MP3 Podcast - Earthbath and Enchanted Home Pet with Michelle Fern

Paul Armstrong returns to the show to talk about something. But then the mouth crimes happened. And then emoji movies, hot mayonnaise and racism got on Denzel Washington's finger, rendering it freaky.We thought it was weird, too. See acast.com/privacy for privacy and opt-out information.

Michelle Fern welcomes Paul Armstrong, CEO and president of earthbath. earthbath's totally natural pet shampoos and products clean gently and naturally, leaving your dogs' coat brilliantly shiny, soft, supple and heavenly smelling. Best of all, they contain no harsh soaps or noxious chemicals, so you never have to worry about what might be left behind on your dog or the environment (or you, for that matter!) In the second segment Michelle chats with Ashleigh Bennett, VP of Sales for Pupsaver. The PupSaver is a small dog car safety seat, created for small breed dogs in need of a safe seat for car rides. Harnesses, crates and booster seats are not the safest options for small dogs, since they offer no impact protection in case of accidents or short stops.! PupSaver offers protection, both for the human occupants of the vehicle and for the pup who is inside it. Questions or Comments? Send them to: michelle@petliferadio.com. More details on this episode MP3 Podcast - earthbath and PupSaver with Michelle Fern

There are few things we love more than absurdity, things that are double black, farts and chores. Somehow, Paul Armstrong has figured out a way to weave all of those things into a tapestry that he drapes himself in and parades through the courtyards of the Internet. Or something like that. See acast.com/privacy for privacy and opt-out information.

The Lux Radio Theatre. November 9, 1936. CBS net. "Alias Jimmy Valentine". Sponsored by: Lux. A good story about a safe-cracker trying to go straight. Pat O'Brien sings "The Charlady's Ball." Guest Melvyn Purvis ("The Greatest G-Man In History") recalls a real safe cracker he met while tracking down John Dillinger.  George Wells (adaptor), Frank Woodruff (director), Charlie Forsyth (sound effects), Allen Jenkins, Cecil B. DeMille, Joan Field (four years old), Melville Ruick (announcer), Pat O'Brien, Melvyn Purvis (intermission guest), O. Henry (author), Paul Armstrong (adaptor), William Frawley, Paul Armstrong (stage adaptor), Carolyn Newell (intermission guest: chorus girl), Crauford Kent, Myra Marsh, Joan Field, Tommy Bupp, Madge Evans, Sam Flint, Rolfe Sedan (doubles), Victor Rodman (doubles), Ken Chavelle (doubles), Virginia Stone (doubles), Jean Colbert (doubles), Frank Nelson (doubles, program opening announcer), Charles Emerson, David Kerman, Ross Forrester, Priscilla Lyon (commercial spokesman), Leora Thatcher (commercial spokesman).oldtimeradiodvd.com

Tonight it's our 3rd annual Halloween Spook-Tacular!! Featuring a CabaRadio radio adventure! A live radio play performed by Circus Maximus Players! Plus we chat with Paul Armstrong about Bloodshots Canada: The 48-Hour Horror Filmmaking Challenge!! Spooky music, upcoming events & so much more!! Tune in at 11pm on CiTR Radio 101.9FM or catch the spookiness online www.citr.caWill Teddy & Eroc survive this year? Listen to find out!!Talk to you later!---------------------------------------------------MISSED A SHOW?Check out all our shows online at http://citr.ca/ under "Shows" or in the Itunes store under citr -- cabaradioDownload them to your MP3 player or listen online to any of the shows at your convenience!http://feeds.feedburner.com/Citr--Cabaradio